1
|
Sabeena S, Ravishankar N, Kalpana MM. Implementation strategies of cervical cancer screening in South Asia: A systematic review. Int J Gynaecol Obstet 2024; 166:483-493. [PMID: 38268412 DOI: 10.1002/ijgo.15366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 12/23/2023] [Accepted: 12/28/2023] [Indexed: 01/26/2024]
Abstract
BACKGROUND Cervical cancer is a preventable cancer by screening, vaccination and timely management of preinvasive cervical lesions. However, about 90% of the global burden of cervical cancer is reported from developing countries. OBJECTIVE This systematic review aimed to analyze the strategies implemented for cervical cancer screening in South Asia. SEARCH STRATEGY An electronic search of PubMed/MEDLINE, Scopus and Google Scholar was carried out for articles published in English, evaluating the implementation of cervical cancer screening between December 2000 and June 2023 in South Asia using appropriate search terms. SELECTION CRITERIA Cross-sectional studies, randomized control trials (RCTs) or non-randomized controlled trials evaluating different cervical screening strategies were included. DATA COLLECTION AND ANALYSIS A three-stage selection process was performed using a validated proforma including the title, author, year of publication, objective, country, study design, screening methods, strategies and outcomes, and results. The systematic review was designed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The risk of bias was evaluated with the National Heart, Lung, and Blood Institute's (NHLBI) Quality Assessment Tools. MAIN RESULTS Out of the initial 1135 articles reviewed systematically, 23 studies met the inclusion criteria and were included in the qualitative synthesis of results. The implementation outcomes measured were acceptability (n = 23 100%), feasibility (n = 22, 95.7%), fidelity (n = 14, 60.9%), sustainability (n = 7, 30.4%), coverage (n = 4, 17.4%) and cost (n = 1, 4.3%). CONCLUSION Cervical cancer screening can be effectively implemented by restructuring the ongoing programs.
Collapse
Affiliation(s)
| | - Nagaraja Ravishankar
- Department of Biostatistics, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India
| | - M M Kalpana
- Department of Obstetrics and Gynecology, Government Medical College, Kozhikode, Kerala, India
| |
Collapse
|
2
|
Bhardwaj PV, Dulala R, Rajappa S, Loke C. Breast Cancer in India: Screening, Detection, and Management. Hematol Oncol Clin North Am 2024; 38:123-135. [PMID: 37330342 DOI: 10.1016/j.hoc.2023.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]
Abstract
Breast cancer is the most common cancer in urban Indian women and the second most common cancer in all Indian women. The epidemiology as well as biology of this cancer seems to be different in the Indian subcontinent when compared with the West. The lack of population-based breast cancer screening programs and delay in seeking a medical consult due to financial and social reasons, including lack of awareness and fear related to a cancer diagnosis, results in delayed diagnosis.
Collapse
Affiliation(s)
- Prarthna V Bhardwaj
- Division of Hematology-Oncology, University of Massachusetts Chan Medical School - Baystate, 759 Chestnut Street, Springfield, MA 01199, USA
| | - Renuka Dulala
- Division of Hematology-Oncology, Holyoke Medical Center, 575 Beech Street, Holyoke, MA 01040, USA
| | - Senthil Rajappa
- Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Road no. 10, Banjara Hills, Hyderabad, Telangana 500034, India
| | - Chandravathi Loke
- Division of Hematology-Oncology, University of Massachusetts Chan Medical School - Baystate, 759 Chestnut Street, Springfield, MA 01199, USA.
| |
Collapse
|
3
|
Mungo C, Orang'o O, Ofner S, Musick B, Yiannoutsos C, Cohen CR, Brown D, Wools-Kaloustian K, Semeere A. Real-World Cervical Cancer Screening Uptake and Predictors of Visual Inspection With Acetic Acid Positivity Among Women Living With HIV in Care Programs in Western Kenya. JCO Glob Oncol 2024; 10:e2300311. [PMID: 38359369 PMCID: PMC10881085 DOI: 10.1200/go.23.00311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/15/2023] [Accepted: 12/08/2023] [Indexed: 02/17/2024] Open
Abstract
PURPOSE To achieve the WHO cervical cancer elimination targets, countries globally must achieve 70% cervical cancer screening (CCS) coverage. We evaluated CCS uptake and predictors of screening positive at two public HIV care programs in western Kenya. METHODS From October 2007 to February 2019, data from the Family AIDS Care and Education Services (FACES) and Academic Model Providing Access to Healthcare (AMPATH) programs in western Kenya were analyzed. The study population included women age 18-65 years enrolled in HIV care. Screening uptake was calculated annually and overall, determining the proportion of eligible women screened. Multivariate logistic regression assessed predictors of positive screening outcomes. RESULTS There were 57,298 women living with HIV (WLWHIV) eligible for CCS across both programs during the study period. The mean age was 31.4 years (IQR, 25.9-37.8), and 39% were on antiretroviral therapy (ART) at the first CCS-eligible visit. Of all eligible women, 29.4% (95% CI, 29.1 to 29.8) underwent CCS during the study period, 27.0% (95% CI, 26.5 to 27.4) in the AMPATH program, and 35.6% (95% CI, 34.9 to 36.4) in the FACES program. Annual screening uptake varied greatly in both programs, with coverage as low as 1% of eligible WLWHIV during specific years. Age at first screening, CD4 count within 90 days of screening, current use of ART, and program (AMPATH v FACES) were each statistically significant predictors of positive screening. CONCLUSION CCS uptake at two large HIV care programs in Kenya fell short of the WHO's 70% screening target. Screening rates varied significantly on the basis of the availability of funding specific to CCS, reflecting the limitations of vertical funding programs.
Collapse
Affiliation(s)
- Chemtai Mungo
- Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC
| | - Omenge Orang'o
- Academic Model Providing Access to Healthcare, Moi University, Eldoret, Kenya
| | - Susan Ofner
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN
| | - Beverly Musick
- Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN
| | - Constantin Yiannoutsos
- Department of Biostatistics and Health Data Science, Indiana University R.M. Fairbanks School of Public Health, Indianapolis, IN
| | - Craig R. Cohen
- Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA
- Family AIDS Care & Education Services, Kenya Medical Research Institute, Kisumu, Kenya
| | - Darron Brown
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| | | | | |
Collapse
|
4
|
Gupta S. Navigating cancer care in India: Reflections & imperatives. Indian J Med Res 2024; 159:117-119. [PMID: 38391138 PMCID: PMC11050746 DOI: 10.4103/ijmr.ijmr_240_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Indexed: 02/24/2024] Open
Affiliation(s)
- Sudeep Gupta
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai 400 012, Maharashtra, India
| |
Collapse
|
5
|
Sharma P, Khanna D, Pradhan S, Birur P. Community cancer screening at primary care level in Northern India: determinants and policy implications for cancer prevention. Fam Med Community Health 2023; 11:e002397. [PMID: 38105243 PMCID: PMC10729271 DOI: 10.1136/fmch-2023-002397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2023] Open
Abstract
OBJECTIVE Despite the established cancer screening programme for oral, breast and cervical cancer by the Government of India, the screening coverage remains inadequate. This study aimed to describe the determinants for oral, breast and cervical cancer prevention in a rural community at the primary care level of Northern India and its policy implications. DESIGN This was a camp-based project conducted for 1 year, using oral visual examination, clinical breast examination and visual inspection of cervix by application of 5% acetic acid according to primary healthcare operational guidelines. During the project, screen-positive participants were followed through reverse navigation. Information about socio-demographic profile, clinical and behavioural history and screening were collected. Predictors for screen-positivity and follow-up compliance were identified through multivariable analysis. SETTINGS Based on the aim of project, one of the remotely located and low socioeconomic rural blocks, having 148 villages (estimated population of 254 285) in Varanasi district, India was selected as the service site. There is an established healthcare delivery and referral system as per the National Health Mission of Government of India. Oral, breast, gallbladder and cervical cancers are the leading cancers in the district. PARTICIPANTS We invited all men and women aged 30-65 years residing in the selected block for the last 6 months for the screening camps. Unmarried women, women with active vaginal bleeding, those currently pregnant and those who have undergone hysterectomy were excluded from cervical cancer screening. RESULTS A total of 14 338 participants were screened through 190 camps and the majority (61.9%) were women. Hindu religion, tobacco use, intention to quit tobacco and presence of symptoms were significantly associated with screen-positivity. Nearly one-third (220; 30.1%) of the screened-positives complied with follow-up. Young age and illiteracy were significantly associated with lower compliance. CONCLUSION Poor follow-up compliance, despite the availability of tertiary cancer care, patient navigation, free transportation and diagnostic services, calls for research to explore the role of contextual factors and develop pragmatic interventions to justify 'close the care gap'. Community cancer screening needs strengthening through cancer awareness, establishing referral system and integration with the National Tobacco Control and Cancer Registry Programmes.
Collapse
Affiliation(s)
- Priyanka Sharma
- Preventive Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India
| | - Divya Khanna
- Preventive Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India
| | - Satyajit Pradhan
- Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India
| | - Praveen Birur
- KLE Society's Institute of Dental Sciences, Bangalore, Karnataka, India
| |
Collapse
|
6
|
Hall MT, Simms KT, Murray JM, Keane A, Nguyen DTN, Caruana M, Lui G, Kelly H, Eckert LO, Santesso N, de Sanjose S, Swai EE, Rangaraj A, Owiredu MN, Gauvreau C, Demke O, Basu P, Arbyn M, Dalal S, Broutet N, Canfell K. Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV. Nat Med 2023; 29:3059-3066. [PMID: 38087116 PMCID: PMC10719091 DOI: 10.1038/s41591-023-02601-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 09/20/2023] [Indexed: 12/17/2023]
Abstract
To support a strategy to eliminate cervical cancer as a public health problem, the World Health Organisation (WHO) reviewed its guidelines for screening and treatment of cervical pre-cancerous lesions in 2021. Women living with HIV have 6-times the risk of cervical cancer compared to women in the general population, and we harnessed a model platform ('Policy1-Cervix-HIV') to evaluate the benefits and harms of a range of screening strategies for women living with HIV in Tanzania, a country with endemic HIV. Assuming 70% coverage, we found that 3-yearly primary HPV screening without triage would reduce age-standardised cervical cancer mortality rates by 72%, with a number needed to treat (NNT) of 38.7, to prevent a cervical cancer death. Triaging HPV positive women before treatment resulted in minimal loss of effectiveness and had more favorable NNTs (19.7-33.0). Screening using visual inspection with acetic acid (VIA) or cytology was less effective than primary HPV and, in the case of VIA, generated a far higher NNT of 107.5. These findings support the WHO 2021 recommendation that women living with HIV are screened with primary HPV testing in a screen-triage-and-treat approach starting at 25 years, with regular screening every 3-5 years.
Collapse
Affiliation(s)
- Michaela T Hall
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
| | - Kate T Simms
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - John M Murray
- School of Mathematics and Statistics, University of New South Wales, Sydney, NSW, Australia
| | - Adam Keane
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - Diep T N Nguyen
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - Michael Caruana
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - Gigi Lui
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - Helen Kelly
- London School of Hygiene and Tropical Medicine, University of London, London, UK
| | - Linda O Eckert
- Department of Global Health and the Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA
| | - Nancy Santesso
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Silvia de Sanjose
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
- ISGlobal, Barcelona, Spain
| | - Edwin E Swai
- Universal Health Coverage and Life Course Cluster, World Health Organization, Dar es Salaam, Tanzania
| | - Ajay Rangaraj
- Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland
| | - Morkor Newman Owiredu
- Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland
| | - Cindy Gauvreau
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
- SUCCESS Project, Expertise France, Paris, France
| | - Owen Demke
- Global Diagnostics, Clinton Health Access Initiative, Kigali, Rwanda
| | - Partha Basu
- Early Detection Prevention and Infections, International Agency for Research on Cancer, Lyon, France
| | - Marc Arbyn
- Cancer Epidemiology Unit, Belgian Cancer Centre, Sciensano, Brussels, Belgium
- Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium
| | - Shona Dalal
- Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland
| | - Nathalie Broutet
- Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
| | - Karen Canfell
- Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| |
Collapse
|
7
|
Chintapally N, Nuwayhid M, Arroju V, Muddu VK, Gao P, Reddy BY, Sunkavalli C. State of cancer care in India and opportunities for innovation. Future Oncol 2023; 19:2593-2606. [PMID: 37675499 DOI: 10.2217/fon-2023-0047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/08/2023] Open
Abstract
Cancer is one of the leading causes of morbidity and mortality in India. Despite recent medical and technological advances, the cancer burden in India remains high and continues to rise. Moreover, substantial regional disparities in cancer incidence and access to essential medical resources exist throughout the country. While innovative and effective cancer therapies hold promise for improving patient outcomes, several barriers hinder their development and utilization in India. Here we provide an overview of these barriers, including challenges related to patient awareness, inadequate infrastructure, scarcity of trained oncology professionals, and the high cost of cancer care. Furthermore, we discuss the limited availability of cancer clinical trials in the country, along with an examination of potential avenues to enhance cancer care in India. By confronting these hurdles head-on and implementing innovative, pragmatic solutions, we take an indispensable step toward a future where every cancer patient in the country can access quality care.
Collapse
Affiliation(s)
- Neha Chintapally
- Pi Health USA, Cambridge, MA, USA
- Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | | | | | - Vamshi K Muddu
- Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India
| | - Peng Gao
- Pi Health USA, Cambridge, MA, USA
| | | | | |
Collapse
|
8
|
Simms KT, Keane A, Nguyen DTN, Caruana M, Hall MT, Lui G, Gauvreau C, Demke O, Arbyn M, Basu P, Wentzensen N, Lauby-Secretan B, Ilbawi A, Hutubessy R, Almonte M, De Sanjosé S, Kelly H, Dalal S, Eckert LO, Santesso N, Broutet N, Canfell K. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med 2023; 29:3050-3058. [PMID: 38087115 PMCID: PMC10719104 DOI: 10.1038/s41591-023-02600-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 09/19/2023] [Indexed: 12/17/2023]
Abstract
In 2020, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer as a public health problem. To support the strategy, the WHO published updated cervical screening guidelines in 2021. To inform this update, we used an established modeling platform, Policy1-Cervix, to evaluate the impact of seven primary screening scenarios across 78 low- and lower-middle-income countries (LMICs) for the general population of women. Assuming 70% coverage, we found that primary human papillomavirus (HPV) screening approaches were the most effective and cost-effective, reducing cervical cancer age-standardized mortality rates by 63-67% when offered every 5 years. Strategies involving triaging women before treatment (with 16/18 genotyping, cytology, visual inspection with acetic acid (VIA) or colposcopy) had close-to-similar effectiveness to HPV screening without triage and fewer pre-cancer treatments. Screening with VIA or cytology every 3 years was less effective and less cost-effective than HPV screening every 5 years. Furthermore, VIA generated more than double the number of pre-cancer treatments compared to HPV. In conclusion, primary HPV screening is the most effective, cost-effective and efficient cervical screening option in LMICs. These findings have directly informed WHO's updated cervical screening guidelines for the general population of women, which recommend primary HPV screening in a screen-and-treat or screen-triage-and-treat approach, starting from age 30 years with screening every 5 years or 10 years.
Collapse
Affiliation(s)
- Kate T Simms
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.
| | - Adam Keane
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Diep Thi Ngoc Nguyen
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Michael Caruana
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Michaela T Hall
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Gigi Lui
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| | - Cindy Gauvreau
- Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
- SUCCESS Project, Expertise France, Paris, France
| | - Owen Demke
- Global Diagnostics, Clinton Health Access Initiative, Kigali, Rwanda
| | - Marc Arbyn
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium
- Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium
| | - Partha Basu
- Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Beatrice Lauby-Secretan
- Evidence Synthesis and Classification Branch, International Agency for Research on Cancer (IARC), Lyon, France
| | - Andre Ilbawi
- Department for the Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization, Geneva, Switzerland
| | - Raymond Hutubessy
- Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
| | - Maribel Almonte
- Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France
- Department of Sexual and Reproductive Health, World Health Organization, Geneva, Switzerland
| | - Silvia De Sanjosé
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
- ISGlobal, Barcelona, Spain
| | - Helen Kelly
- London School of Hygiene & Tropical Medicine, London, UK
| | - Shona Dalal
- Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland
| | - Linda O Eckert
- Department of Global Health, University of Washington, Seattle, WA, USA
- Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
| | - Nancy Santesso
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Nathalie Broutet
- Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
| | - Karen Canfell
- The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
| |
Collapse
|
9
|
Ogunsola OO, Ajayi OA, Ojo TO, Osayi E, Wudiri K, Amoo B, Ayoka-Ikechukwu R, Olumeyan OO, Ifechelobi C, Okonkwo P, Akinro Y. Cervical cancer screening and treatment for PLWHIV: experiences from an innovative program in Nigeria. Reprod Health 2023; 20:125. [PMID: 37633884 PMCID: PMC10463408 DOI: 10.1186/s12978-023-01658-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 07/30/2023] [Indexed: 08/28/2023] Open
Abstract
BACKGROUND We evaluated cervical cancer program for women living with HIV (WLHIV) to determine program screening rate, primary case finder screening accuracy and treatment and post-treatment screening rate among screen-positive patients. METHODS A ten-month review of cervical cancer program data among WLHIV aged 15-49 years on HIV care across forty-one comprehensive ART sites, supported by APIN (a PEPFAR implementing partner) for cervical cancer screening and treatment in Nigeria, was conducted from October 2020 to July 2021. Initial screening was done using visual inspection with acetic acid (VIA) followed by a gynaecologist expert review through a program-designed software named AVIVA, as a confirmatory test. Associations were measured between the primary case finder screening accuracy and study covariates at p-value of 0.05. RESULTS About 10,289 asymptomatic women aged 15-49 years living with HIV were screened for cervical cancer by primary case finders using VIA-based screening test. About 732 (7.1%) had a positive screening test suggestive of precancerous lesions or cervical cancer. Three hundred and fifteen (43.0%) of VIA positive women had treatment using thermal ablation and less than one-third (21.6%) of those treated came back for post-treatment screening test. Primary case finder screening sensitivity, specificity, positive predictive and negative predictive accuracy using gynaecologist review as confirmatory test were 60.8%, 71.5%, 41.7% and 84.5% respectively. Overall screening accuracy was 68.8%. CONCLUSION AND RECOMMENDATIONS This innovative approach to cervical cancer screening among WLHIV yielded modest results in preventing program error and wastages. Wider deployment of expert-based reviews of VIA though AVIVA software might be a veritable approach to improve screening accuracy in low resource settings.
Collapse
|
10
|
Raj S, Kattepur AK, Shylasree T, Mishra GA, Patil A, Pimple S, Noronha S, Pramesh C. Novel educational training of para medical professionals in cervical cancer screening. Gynecol Oncol Rep 2023; 48:101241. [PMID: 37520786 PMCID: PMC10372157 DOI: 10.1016/j.gore.2023.101241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 07/02/2023] [Accepted: 07/09/2023] [Indexed: 08/01/2023] Open
Abstract
Background Cervical cancer is a public health problem in India due to weak national screening policy compounded by lack of resources including scarcity of trained personnel to carry out community-based screening program. Para medical professionals (PMPs) are closely related to women in local communities. Hence, training PMPs by incorporating novel technology and reduced time duration to achieve adequate competence in screening is an area underutilized and needs to be explored. Materials and methods A pilot cross sectional analytical study was conducted at a tertiary referral cancer center using a shorter version of educational intervention of 2 weeks duration (EI2W) involving PMPs. Pre- and post-training assessment of knowledge, attitude, and practice (KAP) was done using questionnaires consisting of 5 domains viz. awareness of cervical cancer, awareness of cervical pre-cancer, practical screening methodology (practice oriented), data management and aspects of human papilloma virus (HPV). Wilcoxon signed-rank test was used for comparison and the degree of change was measured using analysis of covariance (ANCOVA). A p value of <0.05 was considered significant. Results 118 PMPs were included. There was a significant improvement in scores of all domains (except cervical pre-cancer domain), following introduction of EI2W. Knowledge scores, post EI2W was better in Auxiliary Nurse Midwives (ANMs) than other participants. Awareness regarding cervical cancer was higher with more years of experience. The KAP analysis showed excellent interrater reliability in the practice 0.726 (0.649-0.792) followed by knowledge domain 0.711 (0.626-0.783). Conclusion EI2W was effective in significantly improving the competence of PMPs, thus reducing human resource constraints in cervical cancer prevention and elimination.
Collapse
Affiliation(s)
- Sneha Raj
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
| | - Abhay K. Kattepur
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
- Department of Surgical Oncology, Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka, India
| | - T.S. Shylasree
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
- Gynecological Oncology, Aberdeen Royal Infirmary, Foresterhill Road, Aberdeen AB25 2ZN, United Kingdom
| | - Gauravi A Mishra
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
| | - Akshay Patil
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
- Royal Papworth NHS Foundation Trust, University of Cambridge, Cambridge CB2 0AY, England
| | - Sharmila Pimple
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
| | - Santosh Noronha
- Department of Chemical Engineering, Indian Institute of Technology (IIT) Bombay, Powai, Mumbai, India
| | - C.S. Pramesh
- Department of Gynecological Oncology and Preventive Oncology, Tata Memorial Centre, Dr Ernst Borges Marg, Parel, Mumbai 400012, India
| |
Collapse
|
11
|
Perkins RB, Smith DL, Jeronimo J, Campos NG, Gage JC, Hansen N, Rodriguez AC, Cheung LC, Egemen D, Befano B, Novetsky AP, Martins S, Kalpathy-Cramer J, Inturrisi F, Ahmed SR, Marcus J, Wentzensen N, de Sanjose S, Schiffman M. Use of risk-based cervical screening programs in resource-limited settings. Cancer Epidemiol 2023; 84:102369. [PMID: 37105017 DOI: 10.1016/j.canep.2023.102369] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/29/2023] [Accepted: 04/16/2023] [Indexed: 04/29/2023]
Abstract
Cervical cancer screening and management in the U.S. has adopted a risk-based approach. However, the majority of cervical cancer cases and deaths occur in resource-limited settings, where screening and management are not widely available. We describe a conceptual model that optimizes cervical cancer screening and management in resource-limited settings by utilizing a risk-based approach. The principles of risk-based screening and management in resource limited settings include (1) ensure that the screening method effectively separates low-risk from high-risk patients; (2) directing resources to populations at the highest cancer risk; (3) screen using HPV testing via self-sampling; (4) utilize HPV genotyping to improve risk stratification and better determine who will benefit from treatment, and (5) automated visual evaluation with artificial intelligence may further improve risk stratification. Risk-based screening and management in resource limited settings can optimize prevention by focusing triage and treatment resources on the highest risk patients while minimizing interventions in lower risk patients.
Collapse
Affiliation(s)
- Rebecca B Perkins
- Boston University Chobanian and Avedisian School of Medicine/Boston Medical Center, Boston, MA, USA.
| | | | | | - Nicole G Campos
- Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | | | | | | | - Li C Cheung
- National Cancer Institute, Bethesda, MD, USA
| | | | - Brian Befano
- Information Management Services Inc, 3901 Calverton Blvd Suite 200, Calverton, MD, USA
| | - Akiva P Novetsky
- Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | | | | | | | - Syed Rakin Ahmed
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, MA 02115, USA; Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH 02139,USA
| | - Jenna Marcus
- Feinberg School of Medicine at Northwestern University, Chicago, IL, USA
| | | | - Silvia de Sanjose
- National Cancer Institute, Bethesda, MD, USA; ISGlobal, Barcelona, Spain
| | | |
Collapse
|
12
|
Hu SY, Zhao XL, Zhao FH, Wei LH, Zhou Q, Niyazi M, Liu JH, Wang CY, Li LY, Cheng XD, Duan XZ, Sauvaget C, Qiao YL, Sankaranarayanan R. Implementation of visual inspection with acetic acid and Lugol's iodine for cervical cancer screening in rural China. Int J Gynaecol Obstet 2023; 160:571-578. [PMID: 35871356 DOI: 10.1002/ijgo.14368] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 03/08/2022] [Accepted: 07/20/2022] [Indexed: 01/20/2023]
Abstract
OBJECTIVE To address the value of visual inspection where HPV-based screening is not yet available, we evaluated the real-world effectiveness of visual inspection with acetic acid (VIA) and with Lugol's iodine (VILI) as a primary screening method for cervical cancer in rural China. METHODS A total of 206 133 women aged 30-59 years received two rounds of VIA/VILI screening for cervical cancer in 2006-2010. Women with positive screening results underwent colposcopy and direct biopsy, and were treated if cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was diagnosed. Clinical effectiveness of VIA/VILI was evaluated by process and outcome measures. RESULTS The VIA/VILI positivity rate, biopsy rate and detection rate of CIN2+ in the second round were significantly lower than in the first round. The 2-year cumulative detection rate of CIN2+ varied from 0.53% to 0.90% among the four cohorts initiated in 2006, 2007, 2008, and 2009. The first round of screening detected 60%-83% of CIN2, 70%-86% of CIN3, and 88%-100% of cervical cancer. Over 92% of CIN2+ were found at the early stage. CONCLUSION Multiple rounds of visual inspection with continuous training and quality assurance could act as a temporary substitutional screening method for cervical cancer in resource-restricted settings.
Collapse
Affiliation(s)
- Shang-Ying Hu
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xue-Lian Zhao
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Fang-Hui Zhao
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Li-Hui Wei
- Peking University People's Hospital, Beijing, China
| | - Qi Zhou
- Chongqing University Cancer Hospital, Chongqing, China
| | - Mayinuer Niyazi
- People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
| | - Ji-Hong Liu
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
| | - Chun-Yan Wang
- Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
| | - Long-Yu Li
- Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China
| | - Xiao-Dong Cheng
- Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
| | | | - Catherine Sauvaget
- Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France
| | - You-Lin Qiao
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | |
Collapse
|
13
|
Parikh PM, Mullapally SK, Hingmire S, Kamal Uddin AFM, Thinn MM, Shahi A, Tshomo U, Mohan I, Kaur S, Ghadyalpatil N. Cervical Cancer in SAARC Countries. South Asian J Cancer 2023; 12:1-8. [PMID: 36851937 PMCID: PMC9966176 DOI: 10.1055/s-0043-1764227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
Abstract
Purvish M. ParikhIn the year 2020, a total of 342 000 women were estimated to die of cervical cancer, of which 90%) were expected amongst low- and middle-income countries (LMIC). Globally incidence of cervical cancer has reduced as a result of improved personal hygiene, better living conditions and higher application of opportunistic screening programs. Yet GLOBOCAN shows that absolute number of cases are still increasing. We therefore conducted a 21 question multiple choice questionnaire online survey in Jan 2023 amongst 9 SAARC countries. A total of 367 replies were received and the representative answers for each country are being reported in this manuscript. A good possibility of achieving World Health Assembly target (Nov 17, 2020) was felt only by Bhutan and Nepal. For screening, most countries (Bhutan, India, Myanmar, Nepal, Pakistan and Sri Lanka) recommend for all asymptomatic eligible patients. Public health experts have suggested VIA / VILI as the best solution for LMICs. However, a dual screening strategy (HPV DNA plus) cytology was preferred by doctors in Afghanistan, Bhutan, India, Myanmar, Pakistan and Sri Lanka. Screening, triage and then treatment was the preferred by Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka. HPV vaccination was recommended in all girls between ages 10 to 26 years in Bangladesh, India, Myanmar, Nepal, Pakistan and Sri Lanka. All the 9 countries would use HPV vaccination to all eligible patients if the cost of the vaccine was reasonably low. Our survey clearly outlines challenges faced in tackling cervical cancer in SAARC countries. We also provide consensus regarding several potential solutions that can be used in both public and private cervical cancer control programs.
Collapse
Affiliation(s)
- Purvish M Parikh
- Department of Clinical Hematology, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India
| | | | - Sachin Hingmire
- Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
| | - A F M Kamal Uddin
- Department of Radiation Oncology, National Institute of ENT, Dhaka, Bangladesh
| | - M M Thinn
- Department of Gynaecology, Yangon Central Women's Hospital, Yangon, Myanmar
| | - Arun Shahi
- Department of Medical Oncology, Patan Academy of Health Sciences, Kathmandu, Nepal
| | - Ugyen Tshomo
- Department of Gynaecology, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan
| | - Indu Mohan
- Department of Community Medicine, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India
| | - Satinder Kaur
- Department of Gynaecological Oncology, Dharamshila Narayana Superspeciality Hospital, New Delhi, India
| | - Nikhil Ghadyalpatil
- Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana, India
| |
Collapse
|
14
|
Badwe RA, Goel NS. Tata Memorial Hospital: a Peerless Icon. Indian J Surg Oncol 2022; 13:27-29. [PMID: 36691510 PMCID: PMC9859962 DOI: 10.1007/s13193-022-01588-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 07/09/2022] [Indexed: 01/26/2023] Open
Abstract
Few institutes last long and fewer maintain their pre-eminent position throughout their life. They are called temples of their silo. Tata Memorial Hospital and Centre (TMC) is one such temple of healing. The contribution of TMC in patient care, education and research is unique and reasons for its success are varied. It is probably the best expression of Tata culture, Government's commitment, dedication and autonomy of people who ran it. A glimpse into the journey with its changing vision towards a pointed mission of conquest of cancer in India is captured in words.
Collapse
|
15
|
Kulkarni R, Gupta S. Gynaecological Oncology in India: Past, Present and Future. Indian J Surg Oncol 2022; 13:76-80. [PMID: 36691500 PMCID: PMC9860008 DOI: 10.1007/s13193-022-01668-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 10/14/2022] [Indexed: 11/07/2022] Open
Abstract
Gynaecological cancers contribute to a substantial portion of the global cancer burden. Traditionally, these cancers have been treated by generalists, including gynaecologists and surgeons. However, owing to increasing sophistication and challenges in their management, a new sub-speciality of Gynaecologic Oncology, dedicated to these women's comprehensive care, has emerged in recent times. The emergence and evolution of this sub-speciality will facilitate a holistic approach to treating women suffering from gynaecological cancers, including tailored surgical techniques, fertility preservation, precision medicine, hormone modulators, targeted therapy and immunotherapy, which can be achieved within the framework of multidisciplinary management. Hence, we decided to write this synopsis to shed light on the evolution of this discipline in India and offer current and future perspectives.
Collapse
Affiliation(s)
- Rohini Kulkarni
- Department of Gynaecological Oncology, Tata Memorial Centre, Homi Baba National Institute, Mumbai, 400012 India
| | - Sudeep Gupta
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, 400012 Maharashtra India
| |
Collapse
|
16
|
Perkins R, Jeronimo J, Hammer A, Novetsky A, Guido R, Del Pino M, Louwers J, Marcus J, Resende C, Smith K, Egemen D, Befano B, Smith D, Antani S, de Sanjose S, Schiffman M. Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images. Gynecol Oncol 2022; 167:89-95. [PMID: 36008184 DOI: 10.1016/j.ygyno.2022.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 08/01/2022] [Accepted: 08/02/2022] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Colposcopy is an important part of cervical screening/management programs. Colposcopic appearance is often classified, for teaching and telemedicine, based on static images that do not reveal the dynamics of acetowhitening. We compared the accuracy and reproducibility of colposcopic impression based on a single image at one minute after application of acetic acid versus a time-series of 17 sequential images over two minutes. METHODS Approximately 5000 colposcopic examinations conducted with the DYSIS colposcopic system were divided into 10 random sets, each assigned to a separate expert colposcopist. Colposcopists first classified single two-dimensional images at one minute and then a time-series of 17 sequential images as 'normal,' 'indeterminate,' 'high grade,' or 'cancer'. Ratings were compared to histologic diagnoses. Additionally, 5 colposcopists reviewed a subset of 200 single images and 200 time series to estimate intra- and inter-rater reliability. RESULTS Of 4640 patients with adequate images, only 24.4% were correctly categorized by single image visual assessment (11% of 64 cancers; 31% of 605 CIN3; 22.4% of 558 CIN2; 23.9% of 3412 < CIN2). Individual colposcopist accuracy was low; Youden indices (sensitivity plus specificity minus one) ranged from 0.07 to 0.24. Use of the time-series increased the proportion of images classified as normal, regardless of histology. Intra-rater reliability was substantial (weighted kappa = 0.64); inter-rater reliability was fair ( weighted kappa = 0.26). CONCLUSION Substantial variation exists in visual assessment of colposcopic images, even when a 17-image time series showing the two-minute process of acetowhitening is presented. We are currently evaluating whether deep-learning image evaluation can assist classification.
Collapse
Affiliation(s)
- Rebecca Perkins
- Boston University School of Medicine/Boston Medical Center, Boston, MA, USA.
| | | | - Anne Hammer
- Department of Obstetrics and Gynecology, Gødstrup Hospital, NIDO - centre for research and education, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Akiva Novetsky
- Westchester Medical Center/New York Medical College, Valhalla, NY, USA
| | - Richard Guido
- University of Pittsburgh, Magee-Womens Hospital, Pittsburgh, PA, USA
| | - Marta Del Pino
- Clínic Institute of Gynecology, Obstetrics, and Neonatology (ICGON), Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Barcelona University, Medicine Faculty, Barcelona, Spain
| | - Jaqueline Louwers
- Diakonessenhuis, department of Obstetrics and Gynecology, Utrecht, the Netherlands
| | - Jenna Marcus
- Feinberg School of Medicine at Northwestern University, Chicago, IL, USA
| | | | - Katie Smith
- University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | | | - Brian Befano
- Information Management Services Inc, 3901 Calverton Blvd Suite 200, Calverton, MD, USA
| | - Debi Smith
- National Cancer Institute, Bethesda, MD, USA
| | - Sameer Antani
- National Library of Medicine, National Institutes of Health, Bethesda, MD, USA
| | - Silvia de Sanjose
- National Cancer Institute, Bethesda, MD, USA; ISGlobal, Barcelona, Spain
| | | |
Collapse
|
17
|
Adewumi K, Nishimura H, Oketch SY, Adsul P, Huchko M. Barriers and Facilitators to Cervical Cancer Screening in Western Kenya: a Qualitative Study. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2022; 37:1122-1128. [PMID: 33411253 PMCID: PMC9257902 DOI: 10.1007/s13187-020-01928-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/22/2020] [Indexed: 06/12/2023]
Abstract
About nine out of 10 cervical cancer deaths occur in low-resource countries, with a particularly high burden in sub-Saharan Africa. The objectives of this study were to assess barriers and facilitators to cervical cancer screening in western Kenya from the perspectives of community members and healthcare providers. We conducted two focus groups with female community members (n = 24) and one with providers (n = 12) in Migori County, Kenya. Discussion guides queried about knowledge and awareness of cervical cancer prevention; structural, social, and personal barriers; and facilitators towards cervical cancer screening uptake. Group discussions were recorded, transcribed, and analyzed for emerging themes. Participants in both groups reported low awareness of HPV and cervical cancer screening in the community, and identified that as a main barrier to screening. Community members reported fear of pain and embarrassment as significant barriers to a screening pelvic exam. They also reported that providers' lack of knowledge and discomfort with a sensitive subject were significant barriers. A personal connection to cervical cancer and/or screening was associated with willingness to screen and awareness. Providers reported workload and lack of supplies and trained staff as significant barriers to offering services. Based on these findings, we identified three intervention components to address these facilitators and barriers to screening. They include utilizing existing social networks to expand awareness of cervical cancer risk and screening, training non-physician health workers to meet the demand for screening, and employing female-driven screening techniques such as self-collection of specimens for HPV testing. Cervical cancer prevention programs must take into account the local realities in which they occur. In low-resource areas in particular, identifying low-cost, effective, and culturally appropriate strategies for addressing poor screening uptake is important given limited funding. This study took a formative approach to identify facilitators and barriers to cervical cancer screening based on focus groups and interviews with community members and healthcare providers.
Collapse
Affiliation(s)
- Konyin Adewumi
- Duke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC, 27710, USA.
| | - Holly Nishimura
- School of Public Health, University of California at Berkeley, Berkeley, CA, USA
| | - Sandra Y Oketch
- Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
| | - Prajakta Adsul
- National Cancer Institute/National Institutes of Health, Bethesda, MD, USA
| | - Megan Huchko
- Duke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC, 27710, USA
- Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
| |
Collapse
|
18
|
Hategeka C, Adu P, Desloge A, Marten R, Shao R, Tian M, Wei T, Kruk ME. Implementation research on noncommunicable disease prevention and control interventions in low- and middle-income countries: A systematic review. PLoS Med 2022; 19:e1004055. [PMID: 35877677 PMCID: PMC9359585 DOI: 10.1371/journal.pmed.1004055] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 08/08/2022] [Accepted: 06/21/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND While the evidence for the clinical effectiveness of most noncommunicable disease (NCD) prevention and treatment interventions is well established, care delivery models and means of scaling these up in a variety of resource-constrained health systems are not. The objective of this review was to synthesize evidence on the current state of implementation research on priority NCD prevention and control interventions provided by health systems in low- and middle-income countries (LMICs). METHODS AND FINDINGS On January 20, 2021, we searched MEDLINE and EMBASE databases from 1990 through 2020 to identify implementation research studies that focused on the World Health Organization (WHO) priority NCD prevention and control interventions targeting cardiovascular disease, cancer, diabetes, and chronic respiratory disease and provided within health systems in LMICs. Any empirical and peer-reviewed studies that focused on these interventions and reported implementation outcomes were eligible for inclusion. Given the focus on this review and the heterogeneity in aims and methodologies of included studies, risk of bias assessment to understand how effect size may have been compromised by bias is not applicable. We instead commented on the distribution of research designs and discussed about stronger/weaker designs. We synthesized extracted data using descriptive statistics and following the review protocol registered in PROSPERO (CRD42021252969). Of 9,683 potential studies and 7,419 unique records screened for inclusion, 222 eligible studies evaluated 265 priority NCD prevention and control interventions implemented in 62 countries (6% in low-income countries and 90% in middle-income countries). The number of studies published has been increasing over time. Nearly 40% of all the studies were on cervical cancer. With regards to intervention type, screening accounted for 49%, treatment for 39%, while prevention for 12% (with 80% of the latter focusing on prevention of the NCD behavior risk factors). Feasibility (38%) was the most studied implementation outcome followed by adoption (23%); few studies addressed sustainability. The implementation strategies were not specified well enough. Most studies used quantitative methods (86%). The weakest study design, preexperimental, and the strongest study design, experimental, were respectively employed in 25% and 24% of included studies. Approximately 72% of studies reported funding, with international funding being the predominant source. The majority of studies were proof of concept or pilot (88%) and targeted the micro level of health system (79%). Less than 5% of studies report using implementation research framework. CONCLUSIONS Despite growth in implementation research on NCDs in LMICs, we found major gaps in the science. Future studies should prioritize implementation at scale, target higher levels health systems (meso and macro levels), and test sustainability of NCD programs. They should employ designs with stronger internal validity, be more conceptually driven, and use mixed methods to understand mechanisms. To maximize impact of the research under limited resources, adding implementation science outcomes to effectiveness research and regional collaborations are promising.
Collapse
Affiliation(s)
- Celestin Hategeka
- Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America
| | - Prince Adu
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Allissa Desloge
- School of Public Health, University of Illinois Chicago, Chicago, Illinois, United States of America
| | - Robert Marten
- Alliance for Health Policy and Systems Research, WHO, Geneva, Switzerland
| | | | - Maoyi Tian
- The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
- School of Public Health, Harbin Medical University, Harbin, China
| | - Ting Wei
- The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
| | - Margaret E. Kruk
- Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America
| |
Collapse
|
19
|
Kulkarni VY, Mishra GA, Pimple SA, Shaikh HKA, Awasthi AA. Compliance for Community-Based Cervical Cancer Screening Program among Women of Age 30-65 Years Residing in Low Socioeconomic Settings of Mumbai, India. Indian J Community Med 2022; 47:414-419. [PMID: 36438507 PMCID: PMC9693944 DOI: 10.4103/ijcm.ijcm_536_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 12/09/2020] [Indexed: 06/16/2023] Open
Abstract
BACKGROUND Low participation in screening and poor follow-up are major challenges in implementing population based screening in developing countries. Determinants of participation in a community-based organized cervical cancer screening program are discussed here. OBJECTIVES The objectives were to study factors determining compliance of women for cervical cancer screening in an urban low socioeconomic setting. METHODOLOGY Community-based service program was conducted for screening uterine cervix cancers with a visual inspection of the cervix on the application of 5% acetic acid by trained primary health workers. The process involved the selection of clusters, household surveys, health education, and screening of eligible women for uterine cervix cancer. Logistic regression analysis was conducted to identify determinants of participation in cervical cancer screening. RESULTS A total of 138,383 population were surveyed, of which 21,422 eligible women were contacted and 16,424 (82.50%) complied for screening. According to the results of univariate and multivariate analysis, women belonging to the age group of 30-39 (80.69%), literate women with school level or education up to Senior College (78.97% and 80.86%) (odds ratio [OR], 1.323; P ≤ 0.001) and (OR, 1.402; P ≤ 0.001), belonging to Hindu religion (77.20%), speaking Marathi (77.07%), and with a family history of cancer (81.93%) had higher participation for screening, while women belonging to the Muslim community (73.95%) (OR, 0.743; P ≤ 0.001), speaking other than Marathi and Hindi language (73%) (OR, 0.872; P = 0.017), illiterate women (70.71%), and graduate women (70.78%) had lower participation. CONCLUSION High compliance can be achieved by providing good-quality health education and setting up of screening clinics in vicinity of participating women.
Collapse
Affiliation(s)
- Vasundhara Yalguresh Kulkarni
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
| | - Gauravi Ashish Mishra
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
| | - Sharmila Anil Pimple
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
| | - Heena Kauser Aslam Shaikh
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
| | - Aanchal A Awasthi
- Laboratory of Health Data Analytics & Visualization Environment, Amity Institute of Public Health, Amity University, Noida, Uttar Pradesh, India
| |
Collapse
|
20
|
Ho FDV, Arevalo MVPN, de Claro PTS, Jacomina LE, Germar MJV, Dee EC, Eala MAB. Breast and Cervical Cancer Screening in the Philippines: Challenges and Steps Forward. Prev Med Rep 2022; 29:101936. [PMID: 35959499 PMCID: PMC9361315 DOI: 10.1016/j.pmedr.2022.101936] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 07/21/2022] [Accepted: 07/26/2022] [Indexed: 11/17/2022] Open
Affiliation(s)
| | | | | | - Luisa E. Jacomina
- Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines
| | - Maria Julieta V. Germar
- Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Philippine General Hospital, Manila, Philippines
| | - Edward Christopher Dee
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Michelle Ann B. Eala
- College of Medicine, University of the Philippines, Manila, Philippines
- Corresponding author at: College of Medicine, University of the Philippines, 547 Pedro Gil Street, Manila 1000, Philippines.
| |
Collapse
|
21
|
Moudatsou M, Vouyiouka P, Karagianni-Hatziskou E, Rovithis M, Stavropoulou A, Koukouli S. Knowledge and Use of Cervical Cancer Prevention Services among Social Work and Nursing University Students. Healthcare (Basel) 2022; 10:healthcare10061140. [PMID: 35742191 PMCID: PMC9222924 DOI: 10.3390/healthcare10061140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 06/11/2022] [Accepted: 06/15/2022] [Indexed: 12/31/2022] Open
Abstract
The present study examines: (a) the knowledge of healthcare students on cervical cancer (CC) issues and the use of related preventive services, as well as their association with the field of study and other sociodemographic characteristics; (b) the possible effect of social capital and its parameters. A cross-sectional study was conducted, using a convenience non-probability sampling technique. The final sample consisted of forty-nine social work and fifty-one nursing students. The two groups were similar regarding their sociodemographic characteristics and the knowledge and use of gynecological preventive services. However, the nursing students undertook a PAP smear check-up to a lesser extent (48.6%) compared to social work students (51.4%) (p = 0.026). The social capital scores were high for both groups, but social work students were significantly more ‘Tolerant to diversity’. For the total sample, only the ‘Family and friends connections’ subscale correlated with knowledge about the existing gynecological preventive services. Among the main reasons explaining university students’ avoidance of preventive testing were the feelings of fear and embarrassment associated with the PAP smear test. Given the significance of the future professional roles of healthcare students as information sources and leaders in women’s CC preventive behavior, understanding the individual factors contributing to their own adherence is essential. It is equally important to increase their scientific knowledge through the improvement of academic curricula regarding these issues.
Collapse
Affiliation(s)
- Maria Moudatsou
- Social Work Department, School of Health Sciences, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (P.V.); (E.K.-H.); (S.K.)
- Laboratory of Interdisciplinary Approaches for the Enhancement of Quality of Life, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (M.R.); (A.S.)
- Institute of Agri-Food and Life Sciences, Hellenic Mediterranean University Research Centre, Hellenic Mediterranean University, GR-71410 Heraklion, Greece
- Correspondence: ; Tel.: +30-6938980463
| | - Panayiota Vouyiouka
- Social Work Department, School of Health Sciences, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (P.V.); (E.K.-H.); (S.K.)
| | - Eleni Karagianni-Hatziskou
- Social Work Department, School of Health Sciences, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (P.V.); (E.K.-H.); (S.K.)
| | - Michael Rovithis
- Laboratory of Interdisciplinary Approaches for the Enhancement of Quality of Life, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (M.R.); (A.S.)
- Institute of Agri-Food and Life Sciences, Hellenic Mediterranean University Research Centre, Hellenic Mediterranean University, GR-71410 Heraklion, Greece
- Nursing Department, School of Health Sciences, Hellenic Mediterranean University, GR-71410 Heraklion, Greece
| | - Areti Stavropoulou
- Laboratory of Interdisciplinary Approaches for the Enhancement of Quality of Life, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (M.R.); (A.S.)
- Nursing Department, School of Health and Care Sciences, University of West Attica, GR-12243 Athens, Greece
| | - Sofia Koukouli
- Social Work Department, School of Health Sciences, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (P.V.); (E.K.-H.); (S.K.)
- Laboratory of Interdisciplinary Approaches for the Enhancement of Quality of Life, Hellenic Mediterranean University, GR-71410 Heraklion, Greece; (M.R.); (A.S.)
- Institute of Agri-Food and Life Sciences, Hellenic Mediterranean University Research Centre, Hellenic Mediterranean University, GR-71410 Heraklion, Greece
| |
Collapse
|
22
|
Frund C, Kenfack B, Sormani J, Wisniak A, Fouogue JT, Tincho E, Metaxas T, Vassilakos P, Petignat P. Training, Supervision, and Competence Assessment of Cameroonian Health Care Providers Using HPV Self-Sampling, Triage by Visual Inspection, and Treatment by Thermal Ablation in a Single Visit. Front Public Health 2022; 10:875177. [PMID: 35419330 PMCID: PMC8995786 DOI: 10.3389/fpubh.2022.875177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 03/07/2022] [Indexed: 11/15/2022] Open
Abstract
Background Developing human resource capacity and efficient deployment of skilled personnel are essential for cervical cancer screening program implementation in resource-limited countries. Our aim was to provide a context-specific training framework, supervision, and effectiveness evaluation of health care providers in a cervical cancer screening program. Methods A 5-year cervical cancer screening program was implemented in Dschang, West Cameroon. Women were invited to perform human papillomavirus self-sampling (Self-HPV), followed by triage using visual inspection with acetic acid (VIA) and thermal ablation if needed. Health care providers were trained in four key learning phases to perform counseling, screening, and treatment process in a single visit. Training included (i) a 3-day basic course, (ii) 3-day advanced practical training, (iii) 2 weeks of supervision, and (iv) bi-monthly supervision by a mentor. The diagnostic performance of health care providers was compared between two time periods, period I (September 2018 to April 2019) and period II (May 2019 to January 2020), for an overall 17-month study period. Results Fourteen health care providers were recruited for the training course and 12 of them completed the training objectives. Follow-up and evaluations were conducted for three health care providers working in the screening unit at Dschang District Hospital. During the study period, 1,609 women performed Self-HPV, among which 759 were screened during period I and 850 during period II. HPV positivity was 18.2 and 17.1%, and VIA positivity was 45.7 and 71.0% in period I and II, respectively. VIA sensitivity was 60.0% (95% confidence interval [CI] 26.2–87.8) and 80.8% (95% CI 60.6–93.4) in period I and II, respectively (p = 0.390). VIA specificity decreased between period I (57.4, 95% CI 48.1–66.3) and II (30.8, 95% CI 22.6–40.0) (p < 0.001). Health care providers demonstrated substantial agreement with their mentor in their diagnoses during both periods (period I: Cohen's kappa coefficient [k] = 0.73, 95% CI 0.62–0.85, and period II: k = 0.62 0.47–0.76; p = 0.0549). Discussion Training, supervision, and a focus on effectiveness in cervical cancer screening are interventions that contribute to improving frontline provider competencies and maintaining a high quality of health care service delivery.
Collapse
Affiliation(s)
- Chloé Frund
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland
| | - Bruno Kenfack
- Department of Obstetrics Gynecology, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
| | - Jessica Sormani
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.,School of Health Sciences Geneva, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland
| | - Ania Wisniak
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland
| | - Jovanny Tsuala Fouogue
- Department of Obstetrics Gynecology, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
| | - Eveline Tincho
- Faculty of Medicine and Biomedical Sciences, Centre Hospitalier Universitaire (CHUY), Yaoundé, Cameroon
| | - Tania Metaxas
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland
| | - Pierre Vassilakos
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.,Geneva Foundation for Medical Education and Research, Geneva, Switzerland
| | - Patrick Petignat
- Gynecology Division, Department of Gynecology and Obstetrics, University Hospitals of Geneva, Geneva, Switzerland
| |
Collapse
|
23
|
Mullapally SK, Digumarti L, Digumarti R. Cervical Cancer in Low- and Middle-Income Countries: A Multidimensional Approach to Closing the Gaps. JCO Oncol Pract 2022; 18:423-425. [PMID: 35385348 DOI: 10.1200/op.22.00156] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, de Andrade VP, Hunter DJ, Gopal S, Gospodarowicz M, Gunasekera S, Ilbawi A, Kapambwe S, Kingham P, Kutluk T, Lamichhane N, Mutebi M, Orem J, Parham G, Ranganathan P, Sengar M, Sullivan R, Swaminathan S, Tannock IF, Tomar V, Vanderpuye V, Varghese C, Weiderpass E. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 2022; 28:649-657. [PMID: 35440716 PMCID: PMC9108683 DOI: 10.1038/s41591-022-01738-x] [Citation(s) in RCA: 101] [Impact Index Per Article: 50.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 02/09/2022] [Indexed: 01/22/2023]
Abstract
Cancer research currently is heavily skewed toward high-income countries (HICs), with little research conducted in, and relevant to, the problems of low- and middle-income countries (LMICs). This regional discordance in cancer knowledge generation and application needs to be rebalanced. Several gaps in the research enterprise of LMICs need to be addressed to promote regionally relevant research, and radical rethinking is needed to address the burning issues in cancer care in these regions. We identified five top priorities in cancer research in LMICs based on current and projected needs: reducing the burden of patients with advanced disease; improving access and affordability, and outcomes of cancer treatment; value-based care and health economics; quality improvement and implementation research; and leveraging technology to improve cancer control. LMICs have an excellent opportunity to address important questions in cancer research that could impact cancer control globally. Success will require collaboration and commitment from governments, policy makers, funding agencies, health care organizations and leaders, researchers and the public.
Collapse
Affiliation(s)
- C S Pramesh
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
| | - Rajendra A Badwe
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Nirmala Bhoo-Pathy
- Centre for Epidemiology and Evidence-Based Practice, University of Malaya, Kuala Lumpur, Malaysia
| | - Christopher M Booth
- Departments of Oncology and Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | | | - Anna J Dare
- Department of Surgery, University of Toronto, Toronto, Ontario, Canada
| | | | - David J Hunter
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
- Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Satish Gopal
- Centre for Global Health, National Cancer Institute, Rockville, MD, USA
| | - Mary Gospodarowicz
- Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
| | | | | | | | - Peter Kingham
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Tezer Kutluk
- Faculty of Medicine and Cancer Institute, Hacettepe University, Ankara, Turkey
| | | | | | | | | | | | - Manju Sengar
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | | | | | - Ian F Tannock
- Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
| | | | - Verna Vanderpuye
- National Center for Radiotherapy Oncology and Nuclear Medicine and Korle Bu Teaching Hospital, Accra, Ghana
| | | | | |
Collapse
|
25
|
Nguyen DTN, Simms KT, Keane A, Mola G, Bolnga JW, Kuk J, Toliman PJ, Badman SG, Saville M, Kaldor J, Vallely A, Canfell K. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea. BMJ Glob Health 2022; 7:bmjgh-2021-007380. [PMID: 35241461 PMCID: PMC8896000 DOI: 10.1136/bmjgh-2021-007380] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 12/23/2021] [Indexed: 01/22/2023] Open
Abstract
Introduction WHO has launched updated cervical screening guidelines, including provisions for primary HPV screen-and-treat. Papua New Guinea (PNG) has a high burden of cervical cancer, but no national cervical screening programme. We recently completed the first field trials of a screen-and-treat algorithm using point-of-care self-collected HPV and same-day treatment (hereafter self-collected HPV S&T) and showed this had superior clinical performance and acceptability to visual inspection of the cervix with acetic acid (VIA). We, therefore, evaluated the effectiveness, cost-effectiveness and resource implications of a national cervical screening programme using self-collected HPV S&T compared with VIA in PNG. Methods An extensively validated platform (‘Policy1-Cervix’) was calibrated to PNG. A total of 38 strategies were selected for investigation, and these incorporated variations in age ranges and screening frequencies and allowed for the identification of the optimal strategy across a wide range of possibilities. A selection of strategies that were identified as being the most effective and cost-effective were then selected for further investigation for longer-term outcomes and budget impact estimation. In the base case, we assumed primary HPV testing has a sensitivity to cervical intraepithelial neoplasia 2 (CIN2+) + of 91.8% and primary VIA of 51.5% based on our earlier field evaluation combined with evidence from the literature. We conservatively assumed HPV sampling and testing would cost US$18. Costs were estimated from a service provider perspective based on data from local field trials and local consultation. Results Self-collected HPV S&T was more effective and more cost-effective than VIA. Either twice or thrice lifetime self-collected HPV S&T would be cost-effective at 0.5× gross domestic product (GDP) per capita (incremental cost-effectiveness ratio: US$460–US$656/life-years saved; 1GDPper-capita: US$2829 or PGK9446 (year 2019)) and could prevent 33 000–42 000 cases and 23 000–29 000 deaths in PNG over the next 50 years, if scale-up reached 70% coverage from 2023. Conclusion Self-collected HPV S&T was effective and cost-effective in the high-burden, low-resource setting of PNG, and, if scaled-up rapidly, could prevent over 20 000 deaths over the next 50 years. VIA screening was not effective or cost-effective. These findings support, at a country level, WHO updated cervical screening guidelines and indicate that similar approaches could be appropriate for other low-resource settings.
Collapse
Affiliation(s)
| | - Kate T Simms
- Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia
| | - Adam Keane
- Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia
| | - Glen Mola
- Department of Reproductive Health, Obstetrics and Gynecology, School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, CND, Papua New Guinea.,Department of Obstetrics and Gynecology, Port Moresby General Hospital, Port Moresby, Papua New Guinea
| | - John Walpe Bolnga
- Department of Obstetrics and Gynecology, Modilion Hospital, Mango, Madang, Papua New Guinea
| | - Joseph Kuk
- Department of Obstetrics and Gynecology, Mt Hagen Provincial Hospital, Mt Hagen, Western Highlands Province, Papua New Guinea
| | - Pamela J Toliman
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.,Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Steven G Badman
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Marion Saville
- Australian Centre for the Prevention of Cervical Cancer, Melbourne, Victoria, Australia
| | - John Kaldor
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
| | - Andrew Vallely
- Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.,Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Karen Canfell
- Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
26
|
Pimple SA, Pahwa V, Mishra GA, Anand KV, Pathuthara S, Biswas SK. Screening for Early Detection of Cervical Cancer in Women Living with HIV in Mumbai, India - Retrospective Cohort Study from a Tertiary Cancer Center. Indian J Med Paediatr Oncol 2022. [DOI: 10.1055/s-0042-1742662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Abstract
Introduction Women living with human immunodeficiency virus (HIV) have an increased risk of persistent human papillomavirus infection (HPV) of developing cervical cancer precursors and are, therefore, considered at higher risk for cervical cancer. Despite the higher risk, screening for cervical cancer is extremely low among HIV-positive women in India.
Objectives Given the limited usefulness of cytology-based screening programs, the current study retrospectively evaluated the comparative performance of visual inspection with 5% acetic acid (VIA), conventional cytology, and human papillomavirus (HPV) testing among HIV-positive women attending the cancer screening clinic at the tertiary cancer center.
Materials and Methods Retrospective analysis of 291 HIV-positive women attending cervical cancer screening services in a tertiary cancer center in Mumbai was undertaken. All underwent simultaneous screening with VIA, Pap cytology, and HPV DNA testing, followed by diagnostic colposcopy and histopathology. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to detect cervical intraepithelial neoplasia (CIN) 2/3 on histology were estimated.
Results The screen positivity rate for cervical cancer screening by VIA, high-risk HPV DNA, and Pap cytology was 35.7, 34.4, and 6.2% respectively. At the CIN2+ disease threshold, the sensitivity, specificity, PPV, and NPV estimates were 80.00% (59.30–93.17), 68.42% (62.46–73.96), 19.23% (15.46–23.67), 97.33% (94.30–98.77) for VIA; 80.00% (68.78–97.45), 70.68% (64.81–76.08), 22.00% (18.22–26.32), 98.43% (95.58–99.45) for HPV DNA; and 64.00% (42.52–82.03), 98.12% (95.67–99.39), 76.19% (56.13–88.89), 96.67% (94.50–98.00) for cytology (HSIL cutoff).
Conclusion The diagnostic performance of VIA and HPV DNA was comparable and better than cytology indicating that VIA as a cost-effective cervical cancer screening test can be incorporated within the services under sexually transmitted diseases /HIV testing and counseling centers within the country.
Collapse
Affiliation(s)
- Sharmila A. Pimple
- Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Vandita Pahwa
- Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Gauravi A. Mishra
- Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Kavita V. Anand
- Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Saleem Pathuthara
- Department of Microbiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Sanjay K. Biswas
- Department of Microbiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| |
Collapse
|
27
|
Kulkarni VY, Mishra GA, Pimple SA, Patil AS, Bajpai J, TS S. Determinants of Compliance for Breast and Cervical Cancers Screening among Female Police Personnel of Mumbai, India—A Cross-Sectional Study. Indian J Med Paediatr Oncol 2022. [DOI: 10.1055/s-0042-1742703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Abstract
Introduction Women working in police force have unique and vital role to play in law enforcement. Although these women have established a secured place for themselves in the police force, they are exposed to several behavioral and health risks apart from job stress. All these can have potentially serious consequences on their well-being.
Objectives To determine the compliance to breast and uterine cervical cancers screening and identify predictors of participation in breast and cervical cancers screening among women police personnel.
Materials and Methods This is a cross-sectional study conducted among the Mumbai police personnel during the period 2019 to 2021. All women working for Mumbai police work force in 12 zones were invited to participate in the study. Temporary clinics for screening were set up in different police stations and eligible participants were enrolled after obtaining written informed consent. This was followed by sociodemographic and risk factor assessment, health education program, screening for common cancers conducted by trained primary health workers (breast by clinical breast examination and uterine cervix by visual inspection with 5% acetic acid). Screen positives were referred according to predefined referral criteria for further investigations and management.
Results A total of 3,017 police women were contacted, among them, 2,629 (87.14%) were eligible for screening, 2,609 (99.24%) participated in health education, and 1,839 (69.95%) complied for breast or cervical cancer screening. Further, compliance for screening of breast and uterine cervix were 1,837 (91.67%) and 1,297 (64.72%). A total of 256 (13.94%) and 217 (11.81%) police women were screen positives for breast and cervical cancers. According to multivariate logistic regression analysis, women younger than 50 years, those who were not married or were widowed or separated, postmenopausal women, and those who did not have shift duties had higher compliance for breast and cervix cancers screening.
Conclusion Good participation for breast and cervical cancers screening was seen among the women police personnel. This study has demonstrated that awareness and screening by simple low-cost methods for breast and cervical cancers screening is easily implementable and can be replicated among the women police force in different states of India.
Collapse
Affiliation(s)
- Vasundhara Y. Kulkarni
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Gauravi A. Mishra
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Sharmila A. Pimple
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Anil S. Patil
- Department of Preventive Oncology, Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Jyoti Bajpai
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Shylasree TS
- Department of Gynecology Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| |
Collapse
|
28
|
Lauby-Secretan B, Mackie A, Wentzensen N. The IARC Perspective on Cervical Cancer Screening. Reply. N Engl J Med 2022; 386:607-608. [PMID: 35139285 DOI: 10.1056/nejmc2119177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
| | - Anne Mackie
- U.K. Department of Health and Social Care, London, United Kingdom
| | | |
Collapse
|
29
|
Risk factors for cervical cancer among distinct populations in low-resource countries: feasibility of cervical cancer screen-and-treat program on ukerewe island of lake victoria, Tanzania. Curr Opin Obstet Gynecol 2022; 34:20-27. [PMID: 34967811 DOI: 10.1097/gco.0000000000000758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
PURPOSE OF REVIEW A mass cervical cancer screening using World Health Organization-endorsed visual inspection with acetic acid (VIA) and cryotherapy triage was conducted over 5 days at Nansio District Hospital on Ukerewe Island, Tanzania in Lake Victoria. The aim was to evaluate the feasibility of a pilot screen-and-treat on a lower resource island and compare the results to previously held screen-and-treats in higher resource mainland settings. RECENT FINDINGS Two hundred and eight-two women underwent VIA on Ukerewe Island during July 2017. The frequency of abnormal VIA screens was nearly twice that observed on the mainland in 2016 (18.4% vs 10.7%, respectively; P = 0.0091). Island women had lower rates of grand multiparity (19.8% vs 26.8%, P = 0.02) and more island women did not know their HIV status (80% vs 50%, P < 0.0001). Overall, 31% of abnormal VIA screens occurred among women under 30 years between the two sites. Due to the cost of transporting CO2 tanks, cryotherapy was nearly twice as expensive on the island as compared to the mainland. SUMMARY Although transfer of an entire pilot screen-and-treat program to Ukerewe Island is feasible and well-received, expenses associated with ferrying equipment may be prohibitive to long-term sustainability. Higher VIA positivity rates were observed on the island.
Collapse
|
30
|
Zhao S, Huang L, Basu P, Domingo EJ, Supakarapongkul W, Ling WY, Ocviyanti D, Rezhake R, Qiao Y, Tay EH, Zhao F. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. Cancer Lett 2022; 525:22-32. [PMID: 34728309 DOI: 10.1016/j.canlet.2021.10.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/11/2021] [Accepted: 10/25/2021] [Indexed: 12/12/2022]
Abstract
Multiple barriers impede the transformation of evidence-based research into implementation of cervical cancer screening in ASEAN countries. This review is the first of its kind to show the disease burden of cervical cancer, progress till date to implement screening and corresponding challenges, and propose tailored solutions to promote cervical cancer prevention in ASEAN. In 2020, approximately 69 000 cervical cancer cases and 38 000 deaths happened in ASEAN, and more than 44% and 63% increases on new cases and deaths are expected in 2040. Only four countries have initiated population-based cervical cancer screening programs, but the participation rate is less than 50% in some countries and even lower than 10% in Myanmar and Indonesia. Inequity and unavailability in service delivery, lack of knowledge and awareness, limited follow-up and treatment capacity, and funding sustainability affect successful scale-up of cervical cancer screening most in ASEAN. Implementing HPV detection-based primary screening, appropriate management of screen-positives, enhancing health education, integrating health services can accelerate reduction of cervical cancer burden in ASEAN. Achieving high screening coverage and high treatment compliance will help ASEAN countries remain aligned to cervical cancer elimination strategies.
Collapse
Affiliation(s)
- Shuang Zhao
- Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Liuye Huang
- Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Partha Basu
- Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France
| | - Efren Javier Domingo
- Department of Obstetrics and Gynecology, University of the Philippines College of Medicine-Philippine General Hospital, Manila, Philippines
| | | | - Woo Yin Ling
- Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Dwiana Ocviyanti
- Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Indonesia/ Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | - Remila Rezhake
- The 3rd Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital), Xinjiang, China
| | - Youlin Qiao
- Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Fanghui Zhao
- Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
| |
Collapse
|
31
|
Mboineki JF, Wang P, Dhakal K, Getu MA, Chen C. The Effect of Peer-Led Navigation Approach as a Form of Task Shifting in Promoting Cervical Cancer Screening Knowledge, Intention, and Practices Among Urban Women in Tanzania: A Randomized Controlled Trial. Cancer Control 2022; 29:10732748221089480. [PMID: 35666651 PMCID: PMC9174555 DOI: 10.1177/10732748221089480] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Even though the government's priorities in preventing cervical cancer are implemented in urban areas, the screening rate remains unsatisfactory at 6%, compared to 70% recommended by the world health organization. The ongoing public health education has not resulted in sufficient screening rates. The study aims to assess peer-led navigation (PLNav) in promoting cervical cancer screening knowledge, intention, and practices among urban women in Tanzania. Since PLNav is the form of task shifting, it involves delegating cervical-cancer-related tasks from healthcare professionals to community health workers (CHWs). METHODS It is a community-based randomized controlled trial conducted in Dar es Salaam in Tanzania March-Sept 2020. The PLNav involved the CHWs delivering health education, counselling and navigation assistance to community women (COMW). The CHWs help women who have never undergone cervical cancer screening (CCS) and those who have undergone CCS but with a precancerous cervical lesion to overcome screening barriers. The data related to PLNav were analyzed by descriptive statistics, an independent-samples t-test, repeated measures ANOVA and linear regression. RESULTS The repeated measures ANOVA across time showed that PLNav intervention on mean knowledge score changes was statistically significant in the intervention group compared with the control group's usual care, [F (1, 43) = 56.9, P < .001]. At the six-month follow-up, 32 (72.7%) out of 44 participants from the intervention group had screened for cervical cancer, and only one participant (2.3%) from the control group screened. The PLNav intervention on CCS uptake changes was statistically significant in the intervention group compared with usual care in the control group [F (1, 43) = 100.4, P < .001]. The effect of time on CCS uptake in the intervention and control groups was statistically significant [F (1.64, 70.62) = 73.4, P < .001]. CONCLUSION Peer-led navigation (PLNav) was effective in promoting cervical cancer screening knowledge, intention, and uptake.
Collapse
Affiliation(s)
- Joanes Faustine Mboineki
- First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.,12636School of Nursing and Health, Zhengzhou University, Zhengzhou, Henan, China.,School of Nursing and Public Health, The University of Dodoma, Tanzania
| | - Panpan Wang
- 12636School of Nursing and Health, Zhengzhou University, Zhengzhou, Henan, China
| | - Kamala Dhakal
- 12636School of Nursing and Health, Zhengzhou University, Zhengzhou, Henan, China
| | - Mikiyas Amare Getu
- 12636School of Nursing and Health, Zhengzhou University, Zhengzhou, Henan, China
| | - Changying Chen
- First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| |
Collapse
|
32
|
Comparative assessment of test characteristics of cervical cancer screening methods for implementation in low-resource settings. Prev Med 2022; 154:106883. [PMID: 34785209 DOI: 10.1016/j.ypmed.2021.106883] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Revised: 11/05/2021] [Accepted: 11/07/2021] [Indexed: 12/31/2022]
Abstract
Cervical cancer disproportionately affects low-resource settings. Papanicolaou, human papillomavirus (HPV), and visual inspection of cervix with acetic acid (VIA) testing, each with different characteristics, will reduce cervical cancer burden. We conducted a critical literature review using PubMed, Cochrane, WHO, and grey literature from 1994 to 2020. We examined efficacy, harms, and comparative effectiveness of screening methods by age, human immunodeficiency virus, provider characteristics, and assessed implementation challenges in low-resource settings. Comprehensive data on utility and efficacy of screening tests indicates that each screening has strengths and shortcomings but all confer acceptable performance. HPV and VIA appear more promising. Primary HPV test-and-treat, self-testing, and co-testing have been studied but data on triage plans, cost, support system, implementation and sustainability is unclear in low-resource settings. HPV testing could help target subgroups of older or higher risk women. VIA offers local capacity-building and scalability. Quality VIA technique after HPV testing is still required to guide post-screening treatments. VIA competencies decline gradually with current standard trainings. Stationary cervicography improves VIA quality but isn't scalable. Affordable smartphones eliminate this barrier, enhance training through mentorship, and advance continuing education and peer-to-peer training. Smartphone-based VIA facilitates cervical image storage for patient education, health promotion, record-keeping, follow-up care, remote expert support, and quality control to improve VIA reliability and reproducibility and reduce mis-diagnoses and burden to health systems. Rather than ranking screening methods using test characteristics alone in study or higher-resource settings, we advocate for scalable strategies that maximize reliability and access and reduce cost and human resources.
Collapse
|
33
|
Vahabi M, Lofters AK, Mishra G, Pimple S, Wong JPH. Family-Centered Sexual Health Intervention to Promote Cervical Cancer Screening Uptake Among Low-income Rural Women in India: A Community-Based Mixed-Method Pilot study (Preprint). JMIR Res Protoc 2021; 11:e35093. [PMID: 36074549 PMCID: PMC9501679 DOI: 10.2196/35093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 04/08/2022] [Accepted: 05/03/2022] [Indexed: 11/13/2022] Open
Abstract
Background Objective Methods Results Conclusions International Registered Report Identifier (IRRID)
Collapse
Affiliation(s)
- Mandana Vahabi
- Daphne Cockwell School of Nursing, Toronto Metropolitan University (formerly known as Ryerson University), Toronto, ON, Canada
| | | | | | | | - Josephine Pui-Hing Wong
- Daphne Cockwell School of Nursing, Toronto Metropolitan University (formerly known as Ryerson University), Toronto, ON, Canada
| |
Collapse
|
34
|
Gadgil D, Sengar M, Pramesh CS, Badwe R, Ranganathan P. Building research capacity in India: The Masters in Clinical Research program at the Tata Memorial Centre. Perspect Clin Res 2021; 12:189-192. [PMID: 34760645 PMCID: PMC8525792 DOI: 10.4103/picr.picr_48_21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 04/06/2021] [Accepted: 04/13/2021] [Indexed: 11/26/2022] Open
Abstract
Clinical research is an essential part of evidence-based medicine. The conduct of high-quality clinical research requires the backing of strong infrastructure, especially well-trained clinical research professionals. Tata Memorial Centre is the largest public cancer center in India and has been offering a Masters degree in Clinical Research since 2014. In this article, we look at the need for clinical research training, the evolution of this course and the impact it has had on clinical research capacity in India
Collapse
Affiliation(s)
- Durga Gadgil
- Research Consultant, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Manju Sengar
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - C S Pramesh
- Department of Administration and Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Rajendra Badwe
- Department of Administration and Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Priya Ranganathan
- Department of Anaesthesiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
35
|
Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, Kupets R, Smith R, Arrossi S, Bendahhou K, Canfell K, Chirenje ZM, Chung MH, Del Pino M, de Sanjosé S, Elfström M, Franco EL, Hamashima C, Hamers FF, Herrington CS, Murillo R, Sangrajrang S, Sankaranarayanan R, Saraiya M, Schiffman M, Zhao F, Arbyn M, Prendiville W, Indave Ruiz BI, Mosquera-Metcalfe I, Lauby-Secretan B. The IARC Perspective on Cervical Cancer Screening. N Engl J Med 2021; 385:1908-1918. [PMID: 34758259 DOI: 10.1056/nejmsr2030640] [Citation(s) in RCA: 125] [Impact Index Per Article: 41.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Véronique Bouvard
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Nicolas Wentzensen
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Anne Mackie
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Johannes Berkhof
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Julia Brotherton
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Paolo Giorgi-Rossi
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Rachel Kupets
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Robert Smith
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Silvina Arrossi
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Karima Bendahhou
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Karen Canfell
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Z Mike Chirenje
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Michael H Chung
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Marta Del Pino
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Silvia de Sanjosé
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Miriam Elfström
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Eduardo L Franco
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Chisato Hamashima
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Françoise F Hamers
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - C Simon Herrington
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Raúl Murillo
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Suleeporn Sangrajrang
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Rengaswamy Sankaranarayanan
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Mona Saraiya
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Mark Schiffman
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Fanghui Zhao
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Marc Arbyn
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Walter Prendiville
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Blanca I Indave Ruiz
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Isabel Mosquera-Metcalfe
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| | - Béatrice Lauby-Secretan
- From the International Agency for Research on Cancer, Lyon (V.B., W.P., B.I.I.R., I.M.M., B.L.-S.), and the National Public Health Agency, Saint-Maurice (F.F.H.) - both in France; the National Cancer Institute, Rockville, MD (N.W., M. Schiffman); Public Health England and Screening, London (A.M.); Amsterdam University Medical Centers, Amsterdam (J. Berkhof); VCS Foundation, Melbourne, VIC (J. Brotherton), Australia; Azienda Unità Sanitaria Locale - IRCCS Reggio Emilia, Reggio Emilia, Italy (P.G.R.); the University of Toronto, Toronto (R.K.); the American Cancer Society (R. Smith), Emory University (M.H.C.), and the Centers for Disease Control and Prevention (M. Saraiya) - all in Atlanta; the Center for the Study of the State and Society, and the National Scientific and Technical Research Council - both in Buenos Aires (S.A.); the Casablanca Cancer Registry, Casablanca, Morocco (K.B.); The Daffodil Centre, a joint venture between the Cancer Council NSW and the University of Sydney, King's Cross, NSW, Australia (K.C.); the University of Zimbabwe College of Health Sciences, Harare (Z.M.C.); Hospital Clínic de Barcelona, Barcelona (M.P.); PATH, Seattle (S. de Sanjosé); Karolinska Institutet, Stockholm (M.E.); McGill University, Montreal (E.F.); Teikyo University, and the National Cancer Center - both in Tokyo (C.H.); the University of Edinburgh, Edinburgh (C.S.H.); Hospital Universitario San Ignacio, Bogota, Colombia (R.M.); the National Cancer Institute, Bangkok, Thailand (S. Sangrajrang); Research Triangle Institute International, New Delhi, India (R. Sankaranarayanan); Chinese Academy of Medical Sciences, Beijing (F.Z.); and Sciensano, Brussels (M.A.)
| |
Collapse
|
36
|
Chinn JO, Runge AS, Dinicu AI, Chang J, Maher JA, Crawford EW, Naaseh A, Cooper EC, Zezoff DC, White KM, Lucas AN, Bera KR, Bernstein M, Hari A, Ziogas A, Tewari SE, Pearre DC, Tewari KS. Visual inspection with acetic acid screening for cervical cancer among women receiving anti-retroviral therapy for human immunodeficiency virus infection in northern Tanzania. J Obstet Gynaecol Res 2021; 47:4365-4370. [PMID: 34614540 DOI: 10.1111/jog.15011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 06/04/2021] [Accepted: 08/27/2021] [Indexed: 11/30/2022]
Abstract
AIM To evaluate visual inspection with acetic acid (VIA) screening for cervical cancer among human immunodeficiency virus (HIV)-positive patients in an East African community. METHODS During a July 2018 cervical cancer screen-and-treat in Mwanza, Tanzania, participants were offered free cervical VIA screening, cryotherapy when indicated, and HIV testing. Acetowhite lesions and/or abnormal vascularity were designated VIA positive in accordance with current guidelines. The association between VIA results and HIV status was compared using Chi-square and Fisher exact tests. RESULTS Eight hundred and twenty-four of 921 consented participants underwent VIA screening and 25.0% (n = 206) were VIA positive. VIA-positive nonpregnant women (n = 147) received cryotherapy and 15 (1.8%) with cancerous-appearing lesions were referred to Bugando Hospital. Sixty-six women were HIV-positive and included 25 diagnosed with HIV at the cervical cancer VIA screening and 41 with a prior diagnosis of HIV who were receiving antiretroviral therapy (ART) at the time of cervical cancer VIA screening. Sixty-four of these 66 patients, were screened with VIA. HIV infection was not associated with VIA findings. Abnormal VIA positive screening was observed in 20.3% (n = 13) of HIV-positive patients and in 24.4% (n = 145) of HIV-negative patients (p = 0.508). A nonsignificant trend of higher VIA positive screens among newly diagnosed HIV patients of 26.1% (n = 6) versus patients with preexisting HIV on ART of 17.1% (n = 7) was observed (p = 0.580). CONCLUSION The unexpected lack of correlation between HIV infection and VIA positivity in a community with access to ART warrants additional research regarding the previously described role of ART in attenuating HPV-mediated neoplasia.
Collapse
Affiliation(s)
- Justine O Chinn
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Ava S Runge
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Andreea I Dinicu
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Jenny Chang
- Department of Medicine, School of Medicine, University of California Irvine, Orange, California, USA
| | - Justine A Maher
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Elizabeth W Crawford
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Ariana Naaseh
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Emma C Cooper
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Danielle C Zezoff
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Kayla M White
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Alexa N Lucas
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Kevin R Bera
- Department of Medical Education, University of California, Irvine College of Medicine, Irvine, California, USA
| | - Megan Bernstein
- Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA
| | - Anjali Hari
- Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA
| | - Argyrios Ziogas
- Department of Medicine, School of Medicine, University of California Irvine, Orange, California, USA
| | | | - Diana C Pearre
- Department of Gynecology Oncology, University of California Irvine, Orange, California, USA
| | - Krishnansu S Tewari
- Department of Gynecology Oncology, University of California Irvine, Orange, California, USA
| |
Collapse
|
37
|
Saha S, Priya SM, Surender A, Jacob RC, George MP, Varghese NM, Kumar N, Eappen N, Kumar PR, Raymond R, Phillips AC, Mathew RT, Vijayan MM, Sukhadhan C, Thomas BM, Marconi SD, Sindhu KN, Oommen AM, John SM. Screening practices for breast and cervical cancer and associated factors, among rural women in Vellore, Tamil Nadu. Indian J Cancer 2021; 0:326251. [PMID: 35017369 DOI: 10.4103/ijc.ijc_83_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Population-based screening coverage for breast and cervical cancer screening in the community is inadequately reported in India. This study assessed screening rates, awareness, and other factors affecting screening, among rural women aged 25-60 years in Vellore, Tamil Nadu. METHODS Women aged 25-60 years, from five randomly selected villages of a rural block were included in this cross-sectional study in Vellore, Tamil Nadu. Households were selected by systematic random sampling, followed by simple random sampling of eligible women in the house. A semi-structured questionnaire was used to assess screening practices, awareness, and other factors related to cervical and breast cancer. RESULTS Although 43.8% and 57.9% were aware of the availability of screening for cervical and breast cancer respectively, screening rates were only 23.4% (95% confidence interval [CI]: 18.4-28.4%) and 16.2% (95% CI: 11.9-20.5%), respectively. Adequate knowledge (score of ≥50%) on breast cancer was only 5.9%, with 27.2% for cervical cancer. Only 16.6% of women had ever attended any health education program on cancer. Exposure to health education (breast screening odds ratio [OR]: 6.89, 95% CI: 3.34-14.21; cervical screening OR: 6.92, 95% CI: 3.42-14.00); and adequate knowledge (breast OR: 4.69, 95% CI: 1.55-14.22; cervix OR: 3.01, 95% CI: 1.59-5.68) were independently associated with cancer screening. CONCLUSION Awareness and screening rates for breast and cervical cancer are low among rural women in Tamil Nadu, a south Indian state with comparatively good health indices, with health education being an important factor associated with screening practices.
Collapse
Affiliation(s)
- Shubhashis Saha
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - S Mohana Priya
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Anu Surender
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Rohan Chacko Jacob
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Michael Philip George
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Namitha Mary Varghese
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Nishant Kumar
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Noel Eappen
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Prabhas Ranjan Kumar
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Riya Raymond
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Ashna Christine Phillips
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Reuben Thomas Mathew
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Miji M Vijayan
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Christina Sukhadhan
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Bincy Mary Thomas
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Sam David Marconi
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Kulandaipalayam Natarajan Sindhu
- The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Anu Mary Oommen
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| | - Sushil Mathew John
- Department of Community Health, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India
| |
Collapse
|
38
|
Staley H, Shiraz A, Shreeve N, Bryant A, Martin-Hirsch PP, Gajjar K. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2021; 9:CD002834. [PMID: 34694000 PMCID: PMC8543674 DOI: 10.1002/14651858.cd002834.pub3] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND This is an update of the Cochrane review published in Issue 5, 2011. Worldwide, cervical cancer is the fourth commonest cancer affecting women. High-risk human papillomavirus (HPV) infection is causative in 99.7% of cases. Other risk factors include smoking, multiple sexual partners, the presence of other sexually transmitted diseases and immunosuppression. Primary prevention strategies for cervical cancer focus on reducing HPV infection via vaccination and data suggest that this has the potential to prevent nearly 90% of cases in those vaccinated prior to HPV exposure. However, not all countries can afford vaccination programmes and, worryingly, uptake in many countries has been extremely poor. Secondary prevention, through screening programmes, will remain critical to reducing cervical cancer, especially in unvaccinated women or those vaccinated later in adolescence. This includes screening for the detection of pre-cancerous cells, as well as high-risk HPV. In the UK, since the introduction of the Cervical Screening Programme in 1988, the associated mortality rate from cervical cancer has fallen. However, worldwide, there is great variation between countries in both coverage and uptake of screening. In some countries, national screening programmes are available whereas in others, screening is provided on an opportunistic basis. Additionally, there are differences within countries in uptake dependent on ethnic origin, age, education and socioeconomic status. Thus, understanding and incorporating these factors in screening programmes can increase the uptake of screening. This, together with vaccination, can lead to cervical cancer becoming a rare disease. OBJECTIVES To assess the effectiveness of interventions aimed at women, to increase the uptake, including informed uptake, of cervical screening. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 6, 2020. MEDLINE, Embase and LILACS databases up to June 2020. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. SELECTION CRITERIA Randomised controlled trials (RCTs) of interventions to increase uptake/informed uptake of cervical screening. DATA COLLECTION AND ANALYSIS Two review authors independently extracted data and assessed risk of bias. Where possible, the data were synthesised in a meta-analysis using standard Cochrane methodology. MAIN RESULTS Comprehensive literature searches identified 2597 records; of these, 70 met our inclusion criteria, of which 69 trials (257,899 participants) were entered into a meta-analysis. The studies assessed the effectiveness of invitational and educational interventions, lay health worker involvement, counselling and risk factor assessment. Clinical and statistical heterogeneity between trials limited statistical pooling of data. Overall, there was moderate-certainty evidence to suggest that invitations appear to be an effective method of increasing uptake compared to control (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.49 to 1.96; 141,391 participants; 24 studies). Additional analyses, ranging from low to moderate-certainty evidence, suggested that invitations that were personalised, i.e. personal invitation, GP invitation letter or letter with a fixed appointment, appeared to be more successful. More specifically, there was very low-certainty evidence to support the use of GP invitation letters as compared to other authority sources' invitation letters within two RCTs, one RCT assessing 86 participants (RR 1.69 95% CI 0.75 to 3.82) and another, showing a modest benefit, included over 4000 participants (RR 1.13, 95 % CI 1.05 to 1.21). Low-certainty evidence favoured personalised invitations (telephone call, face-to-face or targeted letters) as compared to standard invitation letters (RR 1.32, 95 % CI 1.11 to 1.21; 27,663 participants; 5 studies). There was moderate-certainty evidence to support a letter with a fixed appointment to attend, as compared to a letter with an open invitation to make an appointment (RR 1.61, 95 % CI 1.48 to 1.75; 5742 participants; 5 studies). Low-certainty evidence supported the use of educational materials (RR 1.35, 95% CI 1.18 to 1.54; 63,415 participants; 13 studies) and lay health worker involvement (RR 2.30, 95% CI 1.44 to 3.65; 4330 participants; 11 studies). Other less widely reported interventions included counselling, risk factor assessment, access to a health promotion nurse, photo comic book, intensive recruitment and message framing. It was difficult to deduce any meaningful conclusions from these interventions due to sparse data and low-certainty evidence. However, having access to a health promotion nurse and attempts at intensive recruitment may have increased uptake. One trial reported an economic outcome and randomised 3124 participants within a national screening programme to either receive the standard screening invitation, which would incur a fee, or an invitation offering screening free of charge. No difference in the uptake at 90 days was found (574/1562 intervention versus 612/1562 control, (RR 0.94, 95% CI: 0.86 to 1.03). The use of HPV self-testing as an alternative to conventional screening may also be effective at increasing uptake and this will be covered in a subsequent review. Secondary outcomes, including cost data, were incompletely documented. The majority of cluster-RCTs did not account for clustering or adequately report the number of clusters in the trial in order to estimate the design effect, so we did not selectively adjust the trials. It is unlikely that reporting of these trials would impact the overall conclusions and robustness of the results. Of the meta-analyses that could be performed, there was considerable statistical heterogeneity, and this should be borne in mind when interpreting these findings. Given this and the low to moderate evidence, further research may change these findings. The risk of bias in the majority of trials was unclear, and a number of trials suffered from methodological problems and inadequate reporting. We downgraded the certainty of evidence because of an unclear or high risk of bias with regards to allocation concealment, blinding, incomplete outcome data and other biases. AUTHORS' CONCLUSIONS There is moderate-certainty evidence to support the use of invitation letters to increase the uptake of cervical screening. Low-certainty evidence showed lay health worker involvement amongst ethnic minority populations may increase screening coverage, and there was also support for educational interventions, but it is unclear what format is most effective. The majority of the studies were from developed countries and so the relevance of low- and middle-income countries (LMICs), is unclear. Overall, the low-certainty evidence that was identified makes it difficult to infer as to which interventions were best, with exception of invitational interventions, where there appeared to be more reliable evidence.
Collapse
Affiliation(s)
- Helen Staley
- Obstetrics & Gynaecology, Queen Charlotte's & Chelsea Hospital, Imperial College Healthcare NHS Trust, London, UK
| | | | - Norman Shreeve
- Obstetrics & Gynaecology, University of Cambridge Clinical School, Cambridge, UK
| | - Andrew Bryant
- Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK
| | - Pierre Pl Martin-Hirsch
- Gynaecological Oncology Unit, Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust, Preston, UK
| | - Ketankumar Gajjar
- Department of Gynaecological Oncology, 1st Floor Maternity Unit, City Hospital Campus, Nottingham, UK
| |
Collapse
|
39
|
Kumar A, Chopra S, Gupta S. Contribution of Tata Memorial Centre, India, to cervical cancer care: Journey of two decades. Indian J Med Res 2021; 154:319-328. [PMID: 35295006 PMCID: PMC9131759 DOI: 10.4103/ijmr.ijmr_339_21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Cervical cancer continues to be a major public health concern in India and other low- and middle-income countries. Tata Memorial Centre, India, has been at the forefront in providing treatment, developing best practice guidelines for low-cost efficacious interventions, conducting practice-changing randomized trials and engaging in regional and international collaborations for education and research in cervical cancer. This review summarizes how cervical cancer research and clinical care has evolved over the past two decades at the Tata Memorial Centre, right from testing low-cost public health screening of cervical cancers to the incorporation of the latest technological advancements and providing high-quality evidence for therapeutic management of cervical cancer. The various ongoing strategies for improving survival, toxicity reduction, translational research studies, educational activities and teaching programmes initiated by the Tata Memorial Centre at both national and international levels are discussed.
Collapse
Affiliation(s)
- Anuj Kumar
- Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Supriya Chopra
- Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India,For correspondence: Dr Supriya Chopra, Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai 400 012, Maharashtra, India e-mail:
| | - Sudeep Gupta
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| |
Collapse
|
40
|
Ranganathan P, Chinnaswamy G, Sengar M, Gadgil D, Thiagarajan S, Bhargava B, Booth CM, Buyse M, Chopra S, Frampton C, Gopal S, Grant N, Krailo M, Langley R, Mathur P, Paoletti X, Parmar M, Purushotham A, Pyle D, Rajaraman P, Stockler MR, Sullivan R, Swaminathan S, Tannock I, Trimble E, Badwe RA, Pramesh CS. The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncol 2021; 22:e369-e376. [PMID: 34216541 PMCID: PMC8328959 DOI: 10.1016/s1470-2045(21)00077-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 01/27/2021] [Accepted: 02/04/2021] [Indexed: 02/07/2023]
Abstract
Low-income and middle-income countries (LMICs) have a disproportionately high burden of cancer and cancer mortality. The unique barriers to optimum cancer care in these regions necessitate context-specific research. The conduct of research in LMICs has several challenges, not least of which is a paucity of formal training in research methods. Building capacity by training early career researchers is essential to improve research output and cancer outcomes in LMICs. The International Collaboration for Research methods Development in Oncology (CReDO) workshop is an initiative by the Tata Memorial Centre and the National Cancer Grid of India to address gaps in research training and increase capacity in oncology research. Since 2015, there have been five CReDO workshops, which have trained more than 250 oncologists from India and other countries in clinical research methods and protocol development. Participants from all oncology and allied fields were represented at these workshops. Protocols developed included clinical trials, comparative effectiveness studies, health services research, and observational studies, and many of these protocols were particularly relevant to cancer management in LMICs. A follow-up of these participants in 2020 elicited an 88% response rate and showed that 42% of participants had made progress with their CReDO protocols, and 73% had initiated other research protocols and published papers. In this Policy Review, we describe the challenges to research in LMICs, as well as the evolution, structure, and impact of CReDO and other similar workshops on global oncology research.
Collapse
Affiliation(s)
- Priya Ranganathan
- Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
| | - Girish Chinnaswamy
- Division of Paediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Manju Sengar
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Durga Gadgil
- Research Administration Council, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - Shivakumar Thiagarajan
- Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | | | - Christopher M Booth
- Departments of Oncology and Public Health Sciences, Queen's University, Kingston, ON, Canada
| | - Marc Buyse
- International Drug Development Institute, Louvain-la-Neuve, Belgium; Data Science Institute, Hasselt University, Diepenbeek, Belgium
| | | | - Chris Frampton
- Departments of Medicine and Psychological Medicine, University of Otago, Christchurch, New Zealand
| | - Satish Gopal
- Center for Global Health, National Cancer Institute, Rockville, MD, USA
| | | | - Mark Krailo
- Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
| | - Ruth Langley
- Medical Research Council Clinical Trials Unit at University College London, London, UK
| | - Prashant Mathur
- National Centre for Disease Informatics and Research, Bengaluru, India
| | - Xavier Paoletti
- University of Versailles Saint-Quentin-en-Yvelines, Versailles, France; Department of Biostatistics, Institut Curie, Saint-Cloud, France; Department of Statistics for Precision Medicine, INSERM U900, Paris, France
| | - Mahesh Parmar
- Medical Research Council Clinical Trials Unit at University College London, London, UK
| | - Arnie Purushotham
- School of Cancer and Pharmaceutical Sciences, King's College London, London, UK
| | - Douglas Pyle
- American Society of Clinical Oncology, Alexandria, VA, USA
| | - Preetha Rajaraman
- US Department of Health and Human Services, Washington, DC, USA; US Embassy, New Delhi, India
| | - Martin R Stockler
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
| | | | | | - Ian Tannock
- Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
| | - Edward Trimble
- Office of the Director, National Cancer Institute, NIH, US Department of Health and Human Services, Washington, DC, USA
| | - Rajendra A Badwe
- Departments of Administration and Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| | - C S Pramesh
- Departments of Administration and Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
| |
Collapse
|
41
|
Sivaram S, Perkins S, He M, Ginsburg E, Dominguez G, Vedham V, Katz F, Parascandola M, Bogler O, Gopal S. Building Capacity for Global Cancer Research: Existing Opportunities and Future Directions. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2021; 36:5-24. [PMID: 34273100 PMCID: PMC8285681 DOI: 10.1007/s13187-021-02043-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 05/28/2021] [Indexed: 05/21/2023]
Abstract
Cancer incidence and mortality are increasing in low- and middle-income countries (LMICs), where more than 75% of global cancer burden will occur by the year 2040. The primary drivers of cancer morbidity and mortality in LMICs are environmental and behavioral risk factors, inadequate prevention and early detection services, presence of comorbidities, and poor access to treatment and palliation. These same drivers also contribute to marked cancer health disparities in high-income countries. Studying cancer in LMICs provides opportunities to better understand and address these drivers to benefit populations worldwide, and reflecting this, global oncology as an academic discipline has grown substantially in recent years. However, sustaining this growth requires a uniquely trained workforce with the skills to pursue relevant, rigorous, and equitable global oncology research. Despite this need, dedicated global cancer research training programs remain somewhat nascent and uncoordinated. In this paper, we discuss efforts to address these gaps in global cancer research training at the US National Institutes of Health.
Collapse
Affiliation(s)
- Sudha Sivaram
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Susan Perkins
- Center for Cancer Training, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Min He
- Office of Cancer Centers, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Erika Ginsburg
- Center for Cancer Training, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Geraldina Dominguez
- Office of HIV/AIDS Malignancy, National Cancer Institute, National Institutes of Health, 31 Center Dr, Room 3A33, Bethesda, MD 20892‑2440 USA
| | - Vidya Vedham
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Flora Katz
- Fogarty International Center, National Institutes of Health, 31 Center Drive, Building 31, Bethesda, MD 20892-2220 USA
| | - Mark Parascandola
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Oliver Bogler
- Center for Cancer Training, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| | - Satish Gopal
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Bethesda, MD 20892-9760 USA
| |
Collapse
|
42
|
Budukh AM, Dikshit R, Chaturvedi P. Outcome of the randomized control screening trials on oral, cervix and breast cancer from India and way forward in COVID-19 pandemic situation. Int J Cancer 2021; 149:1619-1620. [PMID: 34152021 PMCID: PMC8427005 DOI: 10.1002/ijc.33712] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Accepted: 06/16/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Atul M Budukh
- Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Rajesh Dikshit
- Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Pankaj Chaturvedi
- Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
43
|
Barrios CH, Mano MS. Is Independent Clinical Research Possible in Low- and Middle-Income Countries? A Roadmap to Address Persistent and New Barriers and Challenges. Am Soc Clin Oncol Educ Book 2021; 41:1-10. [PMID: 33830826 DOI: 10.1200/edbk_321335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Cancer is an increasing and significant problem for both high- and low- and middle-income countries. Basic, translational, and clinical research efforts have been instrumental in generating the outstanding improvements we have witnessed over the last few decades, answering important questions, and improving patient outcomes. Arguably, a substantial portion of currently ongoing research is sponsored by the pharmaceutical industy and specifically addresses questions under industry interests, most of which apply to high-income countries, leaving behind problems related to the much larger and underserved population of patients with cancer in low- and middle-income countries. In this scenario, discussing independent academic research is an important challenge, particularly for these countries. Although different countries and institutions face different problems while establishing independent research agendas, some generalizable barriers can be identified. A solid regulatory and ethical framework, a strong and sustainable technical supporting infrastructure, and motivated and experienced investigators are all paramount to build a viable and productive academic research program. Securing funding for research, although not the only hurdle, is certainly one of the most basic hurdles to overcome. Noticeably, and as an added impediment, public and governmental support for cancer research has been decreasing in high-income countries and is almost nonexistent in the rest of the world. We propose an initial careful diagnostic assessment of the research resource scenario of each institution/country and adjustment of the strategic development plan according to four different research resource restriction levels. Although not necessarily applicable to all situations, this model can be helpful if adjusted to each local or regional situation.
Collapse
Affiliation(s)
- Carlos H Barrios
- Oncology Research Center, Hospital São Lucas, PUCRS, Oncoclínicas Group, Porto Alegre, Brazil
| | | |
Collapse
|
44
|
Vidhubala E, Niraimathi K, Shewade HD, Mahadevan S. Cervical Cancer Care Continuum in South India: Evidence from a Community-based Screening Program. J Epidemiol Glob Health 2021; 10:28-35. [PMID: 32175707 PMCID: PMC7310805 DOI: 10.2991/jegh.k.191111.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Accepted: 07/24/2019] [Indexed: 11/01/2022] Open
Abstract
In India, cervical cancer screening is conducted at various levels; however, after screening, the adherence to the cancer care continuum is barely understood. This study evaluated a community-based cancer screening program conducted in a rural setting (Tirunelveli and Tuticorin districts) in South India and reviewed the completion of care continuum. In this longitudinal descriptive study involving secondary data collection, data from the case records of 2192 women who were consecutively screened between March 2015 and May 2016 were included. All women underwent conventional cytology-based screening (Pap smear) and Visual Inspection with Acetic Acid (VIA). Those for whom either test was positive were referred for histopathological confirmation. Patients with confirmed precancerous conditions and unsatisfactory Pap smears were referred for further management. In total, 2192 women were screened [age range, 17-69 years; mean (standard deviation), 39.2 (8.5)]. Common symptom and sign were white discharge per vaginum (34.9%) and cervical erosion (34.4%), respectively. The VIA was positive for 24% (523/2178; 14 women did not cooperate for VIA) and 113 (5.1%) had epithelial cell abnormality in the Pap smear test. Per histopathology findings, one woman had non-keratinizing squamous cell carcinoma. Seven, three, and four had cervical intraepithelial neoplasia I, II and III, respectively. Of 2192, 807 were eligible for referral (597 had positive results on either Pap or VIA). Among the 807 women referred, only 74 (9.2%) women visited the referral center. The follow-up rate was very poor accounting to fragmentation of care continuum. The success of the screening program depends on the completion of the care continuum.
Collapse
Affiliation(s)
- E Vidhubala
- Nellai Cancer Care Center, Udhavum Ullangal, Tirunelveli, Tamil Nadu, India.,Fenivi Research Solutions, Chennai, Tamil Nadu, India
| | - K Niraimathi
- Fenivi Research Solutions, Chennai, Tamil Nadu, India
| | - Hemant Deepak Shewade
- International Union Against Tuberculosis and Lung Disease (The Union), Paris, France.,International Union Against Tuberculosis and Lung Disease (The Union), South East Asia Office, New Delhi, India.,Karuna Trust, Bengaluru, Karnataka, India
| | - Sankar Mahadevan
- Nellai Cancer Care Center, Udhavum Ullangal, Tirunelveli, Tamil Nadu, India
| |
Collapse
|
45
|
Khanna D. Evaluating Knowledge Regarding Cervical Cancer and Its Screening among Woman in Rural India. South Asian J Cancer 2021; 9:141-146. [PMID: 33937136 PMCID: PMC8075625 DOI: 10.1055/s-0041-1723072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Context
Cervical cancer is the most common cancer among rural women of India. However, awareness of cancer of the uterine cervix and its screening coverage among the general population of India remains insufficient.
Aims
The study aims to assess awareness of cervical cancer and its screening among women attending a rural health care center in northern India and determine factors associated with satisfactory knowledge.
Settings and Design
A cross-sectional observational study was done among women attending a rural secondary health care center from Uttar Pradesh, India.
Materials and Methods
A total of 1088 women aged ≥30 years were interviewed using a pretested schedule. Data were collected for biosocial, reproductive, sexual, and personal habits of participants and their partners. Scoring for knowledge related to cervical cancer and its screening was done.
Statistical Analysis Used
Descriptive statistics were calculated. Chi-square test was applied to detect the significant difference in distribution of bio-socio-demographic variables with knowledge score. Statistically significant variables were subjected to multinomial logistic regression. Unadjusted and adjusted odds ratios with 95% confidence interval were calculated as odds of having poor cervical cancer awareness.
p
< 0.05 was considered statistically significant.
Results
Most participants knew about cervical cancer as a type of cancer in women. Very few knew about symptoms, risk factors, and screening of the disease. Illiteracy and multiple sexual contacts were significant predictors of awareness.
Conclusions
The study demonstrates a lack of awareness in women regarding cervical cancer and its prevention, especially among those women who belonged to weaker sections of the society, because of illiteracy and poor socioeconomic status. Lack of awareness is a potential limiting step for a woman to seek cervical cancer screening. Multipronged strategies are needed to improve the level of cervical cancer awareness among women.
Collapse
Affiliation(s)
- Divya Khanna
- Department of Preventive Oncology, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
| |
Collapse
|
46
|
Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncol 2021; 7:379-385. [PMID: 33507236 DOI: 10.1001/jamaoncol.2020.7478] [Citation(s) in RCA: 85] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Importance The burden of cancer falls disproportionally on low-middle-income countries (LMICs). It is not well known how novel therapies are tested in current clinical trials and the extent to which they match global disease burden. Objectives To describe the design, results, and publication of oncology randomized clinical trials (RCTs) and examine the extent to which trials match global disease burden and how trial methods and results differ across economic settings. Design, Setting, and Participants In this retrospective cohort study, a literature search identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. Randomized clinical trials were classified based on World Bank economic classification. Descriptive statistics were used to compare RCT design and results from high-income countries (HICs) and low/middle-income countries (LMICs). Statistical analysis was conducted in January 2020. Main Outcomes and Measures Differences in the design, results, and output of RCTs between HICs and LMICs. Results The study cohort included 694 RCTs: 636 (92%) led by HICs and 58 (8%) led by LMICs. A total of 601 RCTs (87%) tested systemic therapy and 88 RCTs (13%) tested radiotherapy or surgery. The proportion of RCTs relative to global deaths was higher for breast cancer (121 RCTs [17%] and 7% of deaths) but lower for gastroesophageal cancer (38 RCTs [6%] and 14% of deaths), liver cancer (14 RCTs [2%] and 8% of deaths), pancreas cancer (14 RCTs [2%] and 5% of deaths), and cervical cancer (9 RCTs [1%] and 3% of deaths). Randomized clinical trials in HICs were more likely than those in LMICs to be funded by industry (464 [73%] vs 24 [41%]; P < .001). Studies in LMICs were smaller than those in HICs (median, 219 [interquartile range, 137-363] vs 474 [interquartile range, 262-743] participants; P < .001) and more likely to meet their primary end points (39 of 58 [67%] vs 286 of 636 [45%]; P = .001). The observed median effect size among superiority trials was larger in LMICs compared with HICs (hazard ratio, 0.62 [interquartile range, 0.54-0.76] vs 0.84 [interquartile range, 0.67-0.97]; P < .001). Studies from LMICs were published in journals with lower median impact factors than studies from HICs (7 [interquartile range, 4-21] vs 21 [interquartile range, 7-34]; P < .001). Publication bias persisted when adjusted for whether a trial was positive or negative (median impact factor: LMIC negative trial, 5 [interquartile range, 4-6] vs HIC negative trial, 18 [interquartile range, 6-26]; LMIC positive trial, 9 [interquartile range, 5-25] vs HIC positive trial, 25 [interquartile range, 10-48]; P < .001). Conclusions and Relevance This study suggests that oncology RCTs are conducted predominantly by HICs and do not match the global burden of cancer. Randomized clinical trials from LMICs are more likely to identify effective therapies and have a larger effect size than RCTs from HICs. This study suggests that there is a funding and publication bias against RCTs led by LMICs. Policy makers, research funders, and journals need to address this issue with a range of measures including building capacity and capability in RCTs.
Collapse
Affiliation(s)
- J Connor Wells
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.,Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - Shubham Sharma
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada
| | - Joseph C Del Paggio
- Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada
| | - Wilma M Hopman
- Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - Bishal Gyawali
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.,Department of Oncology, Queen's University, Kingston, Ontario, Canada.,Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| | - Deborah Mukherji
- Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
| | - Nazik Hammad
- Department of Oncology, Queen's University, Kingston, Ontario, Canada
| | - C S Pramesh
- Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Ajay Aggarwal
- Institute of Cancer Policy, King's College London, London, United Kingdom.,Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Richard Sullivan
- Institute of Cancer Policy, King's College London, London, United Kingdom
| | - Christopher M Booth
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.,Department of Oncology, Queen's University, Kingston, Ontario, Canada.,Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
47
|
Mittra I, Mishra GA, Dikshit RP, Gupta S, Kulkarni VY, Shaikh HKA, Shastri SS, Hawaldar R, Gupta S, Pramesh CS, Badwe RA. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ 2021; 372:n256. [PMID: 33627312 PMCID: PMC7903383 DOI: 10.1136/bmj.n256] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE To test the efficacy of screening by clinical breast examination in downstaging breast cancer at diagnosis and in reducing mortality from the disease, when compared with no screening. DESIGN Prospective, cluster randomised controlled trial. SETTING 20 geographically distinct clusters located in Mumbai, India, randomly allocated to 10 screening and 10 control clusters; total trial duration was 20 years (recruitment began in May 1998; database locked in March 2019 for analysis). PARTICIPANTS 151 538 women aged 35-64 with no history of breast cancer. INTERVENTIONS Women in the screening arm (n=75 360) received four screening rounds of clinical breast examination (conducted by trained female primary health workers) and cancer awareness every two years, followed by five rounds of active surveillance every two years. Women in the control arm (n=76 178) received one round of cancer awareness followed by eight rounds of active surveillance every two years. MAIN OUTCOME MEASURES Downstaging of breast cancer at diagnosis and reduction in mortality from breast cancer. RESULTS Breast cancer was detected at an earlier age in the screening group than in the control group (age 55.18 (standard deviation 9.10) v 56.50 (9.10); P=0.01), with a significant reduction in the proportion of women with stage III or IV disease (37% (n=220) v 47% (n=271), P=0.001). A non-significant 15% reduction in breast cancer mortality was observed in the screening arm versus control arm in the overall study population (age 35-64; 20.82 deaths per 100 000 person years (95% confidence interval 18.25 to 23.97) v 24.62 (21.71 to 28.04); rate ratio 0.85 (95% confidence interval 0.71 to 1.01); P=0.07). However, a post hoc subset analysis showed nearly 30% relative reduction in breast cancer mortality in women aged 50 and older (24.62 (20.62 to 29.76) v 34.68 (27.54 to 44.37); 0.71 (0.54 to 0.94); P=0.02), but no significant reduction in women younger than 50 (19.53 (17.24 to 22.29) v 21.03 (18.97 to 23.44); 0.93 (0.79 to 1.09); P=0.37). A 5% reduction in all cause mortality was seen in the screening arm versus the control arm, but it was not statistically significant (rate ratio 0.95 (95% confidence interval 0.81 to 1.10); P=0.49). CONCLUSIONS These results indicate that clinical breast examination conducted every two years by primary health workers significantly downstaged breast cancer at diagnosis and led to a non-significant 15% reduction in breast cancer mortality overall (but a significant reduction of nearly 30%in mortality in women aged ≥50). No significant reduction in mortality was seen in women younger than 50 years. Clinical breast examination should be considered for breast cancer screening in low and middle income countries. TRIAL REGISTRATION Clinical Trials Registry of India CTRI/2010/091/001205; ClinicalTrials.gov NCT00632047.
Collapse
Affiliation(s)
- Indraneel Mittra
- Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr Ernest Borges Road, Parel, Mumbai 400 012, Maharashtra, India
| | - Gauravi A Mishra
- Centre for Cancer Epidemiology, Department of Preventive Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Rajesh P Dikshit
- Centre for Cancer Epidemiology, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute, Kharghar, Mumbai, India
| | - Subhadra Gupta
- Centre for Cancer Epidemiology, Department of Preventive Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Vasundhara Y Kulkarni
- Centre for Cancer Epidemiology, Department of Preventive Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Heena Kauser A Shaikh
- Centre for Cancer Epidemiology, Department of Preventive Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Surendra S Shastri
- Centre for Cancer Epidemiology, Department of Preventive Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Rohini Hawaldar
- Research Administration Council, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - Sudeep Gupta
- Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India
| | - C S Pramesh
- Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr Ernest Borges Road, Parel, Mumbai 400 012, Maharashtra, India
| | - Rajendra A Badwe
- Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr Ernest Borges Road, Parel, Mumbai 400 012, Maharashtra, India
| |
Collapse
|
48
|
Nebhinani M, Saini SK. Leveraging role of non-physician health workers in prevention and control of non-communicable diseases in India: Enablers and challenges. J Family Med Prim Care 2021; 10:595-600. [PMID: 34041047 PMCID: PMC8138392 DOI: 10.4103/jfmpc.jfmpc_1516_20] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 09/17/2020] [Accepted: 10/12/2020] [Indexed: 12/15/2022] Open
Abstract
Due to upsurge of non-communicable disease (NCD) burden, there is accentuated emphasis on task sharing and shifting NCDs-related health care delivery to non-physician healthcare workers especially nursing personnel and grass root level health professionals. This narrative review summates role of non-physician health workers, highlights various enablers and challenges while engaging them in delivery of NCD services so as to prevent and control various NCDs in India. Pubmed, Google scholar databases were searched using various keywords and Mesh terminologies. In addition, reference lists of selected articles were also screened. It is concluded that with regular update of knowledge, training, and supervision, these workers can efficiently deliver promotive, preventive, curative, and rehabilitative NCD-related healthcare services to needy. While engagement of this workforce in NCDs mitigation is a transforming concept, it also has its own challenges and issues which need to be explored and addressed in order to utilize this human resource to their maximum potential.
Collapse
Affiliation(s)
- Mamta Nebhinani
- College of Nursing, All India Institute of Medical Sciences Jodhpur, Rajasthan, India
| | - Sushma K. Saini
- National Institute of Nursing Education, PGIMER, Chandigarh, India
| |
Collapse
|
49
|
Jeyapaul S, Oommen AM, Cherian AG, Marcus TA, Malini T, Prasad JH, George K. Feasibility, uptake and real-life challenges of a rural cervical and breast cancer screening program in Vellore, Tamil Nadu, South India. Indian J Cancer 2021; 58:417-424. [PMID: 33402583 DOI: 10.4103/ijc.ijc_271_19] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background Early detection of breast and cervical cancer by organized screening has been found to reduce mortality rates in trials, but documentation of programme results and challenges is rarely done from non-trial settings. This study reports results of a population-based cancer control programme in a rural block in Vellore, Tamil Nadu, population size (116,085), targeting a population of 18,490 women aged 25-60 years, between November 2014 and March 2018. Methods Village-based health education sessions were conducted by social workers, using trained volunteers and health workers to motivate eligible women. Screening was done at a secondary level hospital, by trained general physicians using visual inspection with acetic acid and clinical breast examination, followed by colposcopy, radiological imaging (breast) and biopsy as required. Results A total of 8 volunteers and 17 health workers motivated women for 93 health education and screening sessions, in 46 out of 82 villages. While 1,890/18,490 (10.2 per cent) were screened for breast cancer, 1,783 (9.6 per cent) were screened for cervical cancer, with a yield of 3.4/1,000 for cervical pre-cancer/cancer. The main challenges were creating time for screening activities in a busy secondary hospital and difficulty in ensuring treatment completion of screen-detected cases. Conclusions Population-based cancer screening programs can be offered by secondary hospitals that also run primary care services, to increase screening rates. Clear referral systems need to be established, bearing in mind that social factors, especially poor family support, may pose a threat to treatment, in spite of easy availability of cure.
Collapse
Affiliation(s)
- Shalini Jeyapaul
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Anu M Oommen
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Anne George Cherian
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Tobey Ann Marcus
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Thabitha Malini
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Jasmin H Prasad
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| | - Kuryan George
- Community Health Department, Christian Medical College, Vellore, Tamil Nadu, India
| |
Collapse
|
50
|
Bhatla N, Nessa A, Oswal K, Vashist S, Sebastian P, Basu P. Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. Int J Gynaecol Obstet 2021; 152:40-47. [PMID: 33205399 DOI: 10.1002/ijgo.13486] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 11/16/2020] [Indexed: 11/08/2022]
Abstract
The call for elimination of cervical cancer as a public health problem by the World Health Organization has led to intense focus on the burden of disease, available resources, and the possibility of introducing efficient systems for screening and treatment that allow effective cancer control in limited-resource settings. Presently, the focus is on the introduction of rapid, technologically less-demanding, affordable HPV testing. However, until such tests become widely available, the momentum that has been gained using visual inspection with acetic acid (VIA) should not be lost. Countries with limited resources and a heavy burden of cervical cancer, such as Bangladesh and India, introduced and scaled up VIA-based programs with varying degrees of programmatic organization and performance. Despite its limitations, VIA's simplicity and affordability has allowed these countries to build infrastructure, increase numbers of trained healthcare personnel, and develop a system of multilevel coordination within the health system. Such efforts will have long-term advantages provided that countries have access to an appropriate HPV test and build on their efforts to improve program organization through a strengthened health system, translating lessons learned in program implementation, logistics, and compliance with the new paradigm.
Collapse
Affiliation(s)
- Neerja Bhatla
- Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
| | - Ashrafun Nessa
- Department of Gynecological Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
| | - Kunal Oswal
- Prevention Early Detection Palliative Care Program and Cancer Care, Tata Trusts, Mumbai, India
| | - Shachi Vashist
- Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
| | - Paul Sebastian
- Prevention Early Detection Palliative Care Program and Cancer Care, Tata Trusts, Mumbai, India
| | - Partha Basu
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| |
Collapse
|